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Summary
. The incidence rate in the UK decreased from 120
per million population (pmp) in 2015 to 118 pmp
in 2016 reﬂecting renal replacement therapy
(RRT) initiation for 7,759 new patients.
. The median age of all incident patients was 64.3
years, but this was highly dependent on ethnicity
(66.2 years for White incident patients, 58.7 years
for non-White patients).
. Diabetic renal disease remained the single most
common cause of renal failure treated by RRT
(28.6%).
. By 90 days, 66.6% of patients were on haemodialysis
(HD), 19.6% on peritoneal dialysis (PD), 9.3% had a
functioning transplant (Tx) and 4.6% had died or
stopped treatment.
. The percentage of RRT patients at 90 days who had
a functioning transplant varied between centres
from 0% to 31% (between 2% and 31% for trans-
planting centres and between 0% and 19% for
non-transplanting centres).
. The mean eGFR at the start of RRT was 7.4 ml/min/
1.73 m2 by the CKD-EPI method and 8.5 ml/min/
1.73 m2 by the MDRD method, similar to the
previous ﬁve years.
. Late presentation continued to fall from 23.9% in
2006 to 15.6% in 2016.
. Timeline codes indicated that 6,891 ﬁrst-ever HD
sessions were delivered in 2016 across 62 centres
in England, Wales and Northern Ireland. Of these,
2,581 (37.5%) were classiﬁed as acute HD and the
remaining 4,310 (62.5%) as HD for established
renal failure (ERF). Data relating to the ﬁrst HD
session were available for 5,373 (78.0%) HD starts.
. After centre exclusions, 4,191 (79.7%) of 5,257 time-
line and sessional HD start dates were on the same
day and 97.2% were within two weeks of each other.
These low levels of discordance are unlikely to
meaningfully inﬂuence overall survival data for
HD recipients.
. Of the 2,581 individuals who received acute HD, 790
(30.6%) developed ERF and 1,791 (69.4%) died,
stopped RRT or recovered renal function.
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. It is vital that coding is consistent between centres.
The UK Renal Registry (UKRR) asks clinicians to
use the timeline to record the date of ﬁrst dialysis
and separately, the date on which the patient is
deemed to have reached ERF. This allows patients
who have an acute start to be distinguished from
those whose start on RRT was planned.
Introduction
This chapter contains analyses of UK adults who
started renal replacement therapy (RRT) in 2016. The
methodology and results for these analyses are in four
sections: geographical variations in incidence rates; the
demographic and clinical characteristics of patients
starting RRT; analyses of late presentation and delayed
referral; and analyses of acute haemodialysis sessions.
The data were analysed using SAS 9.3.
Deﬁnitions
The ﬁrst three sections of this chapter consider indi-
viduals who received RRT as a treatment for established
renal failure (ERF). These individuals are considered
‘incident to RRT’ throughout this report. The term ERF
is used synonymously with the terms end stage renal
failure/disease (ESRF/ESRD). Since the 19th Annual
Report, data have also been published for individuals
who received acute haemodialysis (HD), as coded by
their reporting centre. Previously, such individuals were
only reported if their dialysis was subsequently recoded
as being for ERF, when they failed to recover native
renal function. Recoding is automatically applied at 90
days for individuals still on RRT, but can also be applied
at any point between days 0 and 90 by the reporting
centre. Individuals who commenced HD for acute kidney
injury (AKI) and subsequently recovered renal function,
or died within the ﬁrst 90 days of treatment without
receiving an ERF code are reported in the fourth section
of this chapter. These individuals do not feature else-
where in the UKRR report. Figure 1.1 illustrates the
terms used to categorise dialysis as being acute or for
ERF. See appendix B: Deﬁnitions and Analysis Criteria
(www.renalreg.org) for further details. Note that individ-
uals with a failed renal transplant who returned to dialysis
are not included.
NHS England now mandates the collection of data
regarding acute HD sessions. These data will help to
provide a more complete picture of dialysis use in the
UK than has ever before been possible. Sessional HD
data carry no information about whether the dialysis
was for AKI or ERF. Distinguishing between these two
indications depends entirely upon the accuracy of time-
line data provided by centres.
Differences in incidence data may be seen in the 2011
to 2015 numbers now quoted when compared with
previous publications because of retrospective updating
of data in collaboration with renal centres. In addition,
patients with acute kidney injury requiring dialysis may
be coded in the subsequent year as having developed
ERF, allowing the UKRR to backdate the start date of
RRT.
Where applicable, pre-emptive transplant patients
were allocated to their work-up centre, rather than their
transplant centre. This was not possible for all patients
as some centres did not supply the ‘transfer out for
pre-emptive transplant’ timeline codes. Consequently,
some patients remain allocated to their transplanting
centre.
UK Renal Registry coverage
The UKRR received individual patient level data from
70 adult renal centres in the UK (ﬁve in Wales, ﬁve in
Northern Ireland, nine in Scotland, 51 in England).
Time
RRT initiation Day 90
Acute dialysis
Dialysis for established renal failure
Acute start
dialysis
Acute dialysis code
Code indicating established renal failure
Recovery, death
or withdrawal
Death or
withdrawal
Key:
Dialysis started
for established
renal failure
Patient A
Patient B
Patient C
Patient D
Patient E
Fig. 1.1. Example histories for patients starting RRT, illustrating
the use of timeline codes to deﬁne dialysis as being ‘acute’ or for
established renal failure
Patients that follow patterns B–E receive RRT for ERF and are counted as
‘incident to RRT’ throughout this report. Patients that follow pattern A are
not counted as ‘incident to RRT’ and feature only in section four of this
chapter
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Cambridge renal centre (Addenbrooke’s) was unable to
submit 2015 or 2016 data at patient level prior to the
UKRR closing the database and only provided summary
numbers of patients starting RRT by treatment modality.
This centre is therefore excluded from most analyses in
this chapter. Data from centres in Scotland were obtained
from the Scottish Renal Registry. Data on children and
young adults can be found in chapter 4: Demography
of the UK Paediatric Renal Replacement Therapy Popu-
lation in 2016.
Renal Association Guidelines
Table 1.1 lists the relevant items from the Renal
Association Guidelines on the Planning, Initiating and
Withdrawal of Renal Replacement Therapy [1]. Many
of the audit measures are not currently reported by the
UKRR; mainly due to a high proportion of incomplete
data or because the relevant data are not included in
the UKRR dataset. The UKRR is working with the
renal community to improve reporting across all of
these measures.
Table 1.1. Summary of Renal Association (RA) audit measures relevant to RRT incidence
RA audit measure Reported Reason for non-inclusion/comment
Percentage of patients commencing RRT referred ,3 months
and ,12 months before date of starting RRT
Yes UKRR dataset allows reporting on time elapsed
between date ﬁrst seen and start of RRT
Percentage of incident RRT patients followed up for
.3 months in dedicated pre-dialysis or low clearance clinic
No Not in UKRR dataset
Proportion of incident patients on UK transplant waiting list
at RRT initiation
Yes See chapter 9
Proportion of incident RRT patients transplanted pre-
emptively from living donors and cadaveric donors
Yes
Mean eGFR at time of pre-emptive transplantation No Numbers with data were small, the UKRR will
consider doing a combined years analysis in future
reports
Proportion of incident patients commencing peritoneal or
home haemodialysis
Partly See appendix F for proportion starting on PD and
see tables 1.12a and 1.12b for proportion on PD at
90 days. Not reported for home HD due to small
numbers
Proportion of patients who have undergone a formal
education programme prior to initiation of RRT
No Not in UKRR dataset
Proportion of haemodialysis patients who report that they
have been offered a choice of RRT modality
No Not in UKRR dataset
Proportion of patients who have initiated dialysis in an
unplanned fashion who have undergone formal education by
3 months
No Not in UKRR dataset
Evidence of formal continuing education programme for
patients on dialysis
No Not in UKRR dataset
Proportion of incident patients known to nephrology services
for 3 months or more prior to initiation (planned initiation)
Yes
Proportion of planned initiations with established access or
pre-emptive transplantation
Yes See appendix F for proportion of incident patients
having pre–emptive transplantation, and see
chapter 10 for dialysis access
Inpatient/outpatient status of planned initiations No Not in UKRR dataset
Mean eGFR at start of renal replacement therapy Partly Reported but not at centre level due to poor data
completeness
UK Renal Replacement Therapy Incidence
in 2016
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1. Geographical variation in incidence rates
Introduction
Incidence rates vary widely between renal centres.
Equity of access to RRT is hard to assess, many variables
(including medical, social and demographic factors)
inﬂuence rates of ERF. Thus, comparisons of crude
incidence rates by geographical area are misleading. To
enhance comparisons, age and sex standardised rates
for each clinical commissioning group/health board
(CCG/HBs) are presented along with crude rates. Popu-
lation ethnicity rates are presented but adjustment for
ethnicity or comorbidity was not made due to incomplete
data.
Methods
See appendix D: Methodology used for Analyses and appen-
dix E: Methodology for Estimating Catchment Populations
(www.renalreg.org) for a detailed description of methods used to
calculate crude and age/sex standardised incidence ratios and to
estimate catchment populations.
Only one centre (Cambridge) was unable to provide patient-
level data. Aggregrated data enabled estimation of incident
numbers for 2015 and 2016. These estimates are presented in
tables 1.2 and 1.4, but do not feature elsewhere in this chapter.
The 2011 to 2014 data were used to decide which CCG/HBs
should be excluded from the calculation of age and sex standar-
dised rates due to missing patient-level data. Those CCG/HBs
where greater than 15% of the incident RRT population from
2011 to 2014 were incident patients of the Cambridge renal centre
were not included in the analysis for 2015 or 2016. These CCG/
HBs are included for 2011–2014. CCG/HBs where less than 15%
of the 2011–2014 data were from Cambridge were included in
the analyses, and where the percentage was between 5% and
15% are ﬂagged in table 1.3 as their results are likely to be
underestimated.
Results
Overall
In 2016, the number of adult patients starting RRT in
the UK was 7,759 equating to an incidence rate of
118 pmp (table 1.2), compared with 120 pmp in 2015.
Scotland’s rate was notably lower than the rest of the
UK (ﬁgure 1.2). There continued to be very marked sex
differences in incidence rates which were 151 pmp
(95% CI 147–155) in males and 86 pmp (95% CI 83–
90) in females.
The denominators used for these rates were the entire
population i.e. they include under 18-year olds. When
incident patients aged under 18 were included in the
numerator the UK rate was 120 pmp.
Incidence rates at CCG/HB level
Table 1.3 shows incidence rates and standardised inci-
dence ratios for CCG/HBs. There were wide variations
Table 1.2. Number of new adult patients starting RRT in the UK in 2016
Englandb N Ireland Scotlandc Wales UKb
Number starting RRT 6,599 226 559 375 7,759
Total estimated population mid-2016 (millions)a 55.3 1.9 5.4 3.1 65.6
Incidence rate (pmp) 119 121 103 120 118
(95% CI) (117–122) (106–137) (95–112) (108–133) (116–121)
aData from the Ofﬁce for National Statistics, National Records of Scotland and the Northern Ireland Statistics and Research Agency – based
on the 2011 census
bCambridge was unable to submit patient level data for 2015 or 2016 but provided the UKRR with information allowing their incident
numbers for 2015 and 2016 to be estimated. These numbers have been used here and in table 1.4 but not elsewhere in this chapter
cThe number starting RRT, and hence the RRT incidence rate, published in the Scottish Renal Registry report for the same period is slightly
higher at 573 (106 pmp). This is explained by their inclusion of under 18 year olds and other differences in the deﬁnition of incident RRT
patients between the two registries
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Fig. 1.2. RRT incidence rates in the countries of the UK 1990–
2016
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Table 1.3. Crude adult incidence rates (pmp) and age/sex standardised incidence ratios 2011–2016
CCG/HB – CCG in England, Health and Social Care Areas in Northern Ireland, Local Health Boards in Wales and Health Boards in Scotland
O/E – standardised incidence ratio
LCL – lower 95% conﬁdence limit
UCL – upper 95% conﬁdence limit
pmp – per million population
Areas with notably low incidence ratios over six years are italicised in lighter greyed areas, those with notably high incidence ratios over six
years are bold in darker greyed areas – for the full methodology see appendix D
Conﬁdence intervals are not given for the crude rates per million population but ﬁgures D1 and D2 in appendix D can be used to determine
if a CCG/HB falls within the 95% conﬁdence interval around the national average rate
Mid-2016 population data from the Ofﬁce for National Statistics, National Records of Scotland and the Northern Ireland Statistics and
Research Agency – based on the 2011 census
% non-White – percentage of the CCG/HB population that is non-White, from 2011 census
UK area CCG/HB
Total
population
(2016)
2011
O/E
2012
O/E
2013
O/E
2014
O/E
2015
O/E
2016 2011–2016
%
non-
WhiteO/E
Crude
rate
pmp O/E LCL UCL
Crude
rate
pmpa
Cheshire,
Warrington
and Wirral
NHS Eastern Cheshire 196,900 0.75 0.71 0.65 0.72 0.91 0.51 71 0.71 0.59 0.85 92 3.7
NHS South Cheshire 179,800 0.74 0.58 1.14 1.07 0.85 0.69 89 0.85 0.70 1.02 103 2.9
NHS Vale Royal 103,700 0.87 0.78 1.26 0.24 0.45 0.31 39 0.64 0.48 0.85 76 2.1
NHS Warrington 208,800 0.45 0.85 0.70 0.99 0.75 0.64 77 0.73 0.60 0.89 83 4.1
NHS West Cheshire 232,000 1.05 0.86 0.98 0.82 0.78 0.99 129 0.91 0.78 1.07 112 2.8
NHS Wirral 321,200 0.91 0.63 0.99 0.68 1.08 0.94 121 0.88 0.76 1.00 106 3.0
Durham,
Darlington
and Tees
NHS Darlington 105,600 0.86 1.29 0.83 0.55 1.13 0.61 76 0.87 0.69 1.11 103 3.8
NHS Durham Dales, Easington
and Sedgeﬁeld
274,600 1.12 0.85 1.01 0.93 1.00 0.95 124 0.98 0.85 1.12 120 1.2
NHS Hartlepool and Stockton-
on-Tees
288,500 0.93 1.05 0.87 0.97 0.72 0.73 87 0.87 0.75 1.01 98 4.4
NHS North Durham 247,500 0.55 1.25 0.64 0.54 0.71 0.88 109 0.76 0.64 0.90 89 2.5
NHS South Tees 275,800 0.96 0.99 1.23 0.81 1.58 0.99 120 1.10 0.96 1.26 124 6.7
Greater
Manchester
NHS Bolton 283,100 0.96 0.91 0.92 0.68 1.08 1.15 131 0.95 0.82 1.11 102 18.1
NHS Bury 188,700 0.72 1.38 0.79 1.17 1.21 1.13 133 1.07 0.90 1.27 118 10.8
NHS Heywood, Middleton &
Rochdale
216,200 1.23 1.27 1.24 1.39 1.03 1.37 153 1.25 1.08 1.46 131 18.3
NHS Manchester 541,300 1.26 1.45 1.63 1.50 1.77 1.62 133 1.54 1.40 1.71 119 33.5
NHS Oldham 232,700 1.04 0.72 0.96 1.28 1.10 1.43 155 1.10 0.94 1.28 112 22.5
NHS Salford 248,700 0.74 0.87 1.10 0.84 0.84 1.23 129 0.94 0.80 1.11 92 9.9
NHS Stockport 290,600 0.88 0.66 0.52 0.89 0.82 1.02 127 0.80 0.69 0.94 94 7.9
NHS Tameside and Glossop 256,400 0.98 0.60 1.09 0.82 1.01 1.22 144 0.96 0.82 1.12 107 8.2
NHS Trafford 234,700 0.50 1.17 1.14 0.84 0.88 1.03 119 0.93 0.79 1.10 101 14.5
NHS Wigan Borough 323,100 1.01 0.77 0.75 0.92 0.93 1.04 127 0.90 0.79 1.04 104 2.7
Lancashire NHS Blackburn with Darwen 147,000 1.41 1.25 0.93 0.81 1.62 0.98 102 1.17 0.96 1.42 114 30.8
NHS Blackpool 139,200 0.90 1.53 1.18 1.17 0.89 0.56 72 1.03 0.85 1.25 123 3.3
NHS Chorley and South
Ribble
174,300 0.95 0.73 1.27 0.86 1.10 0.65 80 0.93 0.77 1.11 108 2.9
NHS East Lancashire 375,800 0.93 0.55 0.87 1.07 0.65 0.86 104 0.82 0.72 0.94 94 11.9
NHS Fylde & Wyre 169,000 0.55 0.77 0.79 0.96 0.87 0.84 124 0.80 0.67 0.96 111 2.1
NHS Greater Preston 203,500 0.53 1.02 0.85 0.93 1.02 0.69 79 0.84 0.70 1.01 91 14.7
NHS Morecombe Bay 348,500 0.70 0.82 0.70 0.64 0.55 0.49 66 0.64 0.55 0.75 82 4.0
NHS West Lancashire 113,400 0.85 0.77 0.67 0.63 1.21 0.61 79 0.79 0.62 1.01 97 1.9
Merseyside NHS Halton 126,900 1.53 0.98 0.95 1.04 1.32 1.00 118 1.14 0.93 1.39 126 2.2
NHS Knowsley 147,900 1.13 1.32 0.64 1.70 0.87 0.82 95 1.08 0.89 1.30 117 2.8
NHS Liverpool 484,600 1.11 1.22 1.01 1.20 1.16 0.90 95 1.10 0.98 1.23 109 11.1
NHS South Sefton 158,900 1.41 1.06 1.31 1.28 1.03 1.23 157 1.22 1.03 1.44 146 2.2
NHS Southport and Formby 115,400 0.95 0.75 1.39 0.81 0.54 0.72 104 0.85 0.68 1.06 116 3.1
NHS St Helens 178,500 0.76 0.90 0.58 0.96 0.96 0.97 123 0.86 0.71 1.04 103 2.0
UK Renal Replacement Therapy Incidence
in 2016
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Table 1.3. Continued
UK area CCG/HB
Total
population
(2016)
2011
O/E
2012
O/E
2013
O/E
2014
O/E
2015
O/E
2016 2011–2016
%
non-
WhiteO/E
Crude
rate
pmp O/E LCL UCL
Crude
rate
pmpa
Cumbria,
Northumberland,
Tyne and Wear
NHS Cumbria North 318,200 0.65 0.44 1.01 0.88 1.04 0.89 123 0.83 0.72 0.95 107 1.5
NHS Newcastle Gateshead 498,100 0.82 0.85 0.62 0.85 1.05 0.93 102 0.86 0.76 0.97 89 10.1
NHS North Tyneside 203,300 0.67 0.89 0.95 0.65 0.78 0.98 123 0.82 0.69 0.98 97 3.4
NHS Northumberland 316,000 0.82 0.76 0.62 0.94 0.63 0.86 120 0.77 0.67 0.89 102 1.6
NHS South Tyneside 149,400 1.09 0.54 0.76 0.61 0.95 1.43 181 0.90 0.74 1.10 107 4.1
NHS Sunderland 278,000 0.77 0.89 0.61 0.91 0.99 1.26 155 0.91 0.79 1.06 106 4.1
North Yorkshire
and Humber
NHS East Riding of Yorkshire 315,900 0.73 0.70 0.46 0.73 0.81 0.73 104 0.69 0.60 0.80 94 1.9
NHS Hambleton,
Richmondshire and Whitby
153,200 0.69 1.21 0.87 0.82 0.60 0.65 91 0.80 0.65 0.97 106 2.7
NHS Harrogate and Rural
District
156,300 0.97 0.96 0.52 1.07 1.07 1.08 147 0.95 0.79 1.14 122 3.7
NHS Hull 260,200 0.78 0.78 0.95 1.02 1.33 0.98 104 0.98 0.84 1.15 98 5.9
NHS North East Lincolnshire 159,100 1.33 0.69 0.83 1.00 1.00 0.56 69 0.90 0.74 1.09 105 2.6
NHS North Lincolnshire 170,800 1.51 1.14 1.00 0.47 1.00 0.82 105 0.98 0.82 1.17 118 4.0
NHS Scarborough and Ryedale 111,400 0.57 0.92 0.69 0.78 0.62 0.82 117 0.74 0.58 0.94 99 2.5
NHS Vale of York 357,900 1.08 0.92 0.77 0.82 0.63 0.90 112 0.85 0.74 0.97 99 4.0
South Yorkshire
and Bassetlaw
NHS Barnsley 241,200 0.80 1.02 1.03 1.39 0.80 1.21 149 1.05 0.90 1.21 122 2.1
NHS Bassetlaw 114,800 0.82 1.04 1.30 0.89 0.52 0.79 104 0.88 0.71 1.11 110 2.6
NHS Doncaster 306,400 1.07 0.82 1.15 1.37 0.83 1.18 144 1.07 0.94 1.22 122 4.7
NHS Rotherham 261,900 0.67 0.84 0.75 0.90 1.04 0.77 95 0.83 0.71 0.98 97 6.4
NHS Shefﬁeld 575,400 1.00 1.24 0.96 1.02 0.93 0.93 101 1.01 0.91 1.12 103 16.3
West Yorkshire NHS Airedale, Wharfedale and
Craven
160,000 0.49 0.65 0.84 1.14 0.90 0.62 81 0.78 0.64 0.96 96 11.1
NHS Bradford City 84,900 1.86 2.61 2.55 3.12 2.31 2.67 188 2.53 2.04 3.12 169 72.2
NHS Bradford Districts 339,700 1.10 1.40 1.06 1.15 1.57 1.58 165 1.32 1.17 1.49 129 28.7
NHS Calderdale 209,800 0.59 0.77 1.05 0.62 0.71 0.92 110 0.78 0.64 0.94 87 10.3
NHS Greater Huddersﬁeld 245,000 0.91 1.10 0.92 1.01 0.76 0.63 73 0.88 0.75 1.04 97 17.4
NHS Leeds North 201,200 0.84 0.79 0.86 0.90 0.65 0.99 119 0.84 0.70 1.01 95 17.4
NHS Leeds South and East 253,700 0.93 0.75 0.95 0.98 0.62 0.94 95 0.86 0.72 1.03 81 18.3
NHS Leeds West 326,900 0.59 0.73 1.14 0.70 0.88 0.64 64 0.78 0.66 0.92 73 10.8
NHS North Kirklees 192,000 1.24 0.48 1.46 0.84 0.80 1.00 109 0.97 0.80 1.16 100 25.3
NHS Wakeﬁeld 336,800 0.91 1.07 0.85 0.98 0.60 0.87 107 0.88 0.76 1.00 101 4.6
Arden,
Herefordshire
and
Worcestershire
NHS Coventry and Rugby 456,700 1.44 1.75 1.27 1.13 1.04 1.47 153 1.34 1.21 1.49 132 22.2
NHS Herefordshire 189,300 0.82 0.90 0.80 0.91 1.24 0.99 137 0.95 0.81 1.12 124 1.8
NHS Redditch and
Bromsgrove
181,700 0.80 1.18 0.72 0.82 0.78 0.70 88 0.83 0.69 1.00 98 6.0
NHS South Warwickshire 262,700 0.99 0.66 0.58 0.85 0.81 0.87 114 0.80 0.68 0.93 98 7.0
NHS South Worcestershire 301,400 0.71 0.78 0.76 0.95 0.71 0.64 86 0.76 0.65 0.88 96 3.7
NHS Warwickshire North 190,200 1.10 0.80 0.74 1.56 1.08 1.25 158 1.10 0.93 1.29 130 6.5
NHS Wyre Forest 99,900 1.07 0.81 0.64 1.35 0.43 0.87 120 0.86 0.67 1.09 112 2.8
Birmingham
and the Black
Country
NHS Birmingham CrossCity 748,300 1.63 1.49 1.46 1.53 1.62 1.72 170 1.58 1.46 1.70 146 35.2
NHS Birmingham South and
Central
204,000 1.87 1.53 1.66 1.78 1.39 1.82 172 1.67 1.45 1.93 149 40.4
NHS Dudley 317,600 0.86 1.22 1.25 0.91 0.85 0.88 110 0.99 0.87 1.13 116 10.0
NHS Sandwell and West
Birmingham
495,100 1.69 1.47 1.55 1.70 1.85 1.95 190 1.71 1.56 1.87 157 45.3
NHS Solihull 211,800 0.68 1.01 0.90 0.89 1.11 1.08 137 0.95 0.81 1.12 113 10.9
NHS Walsall 278,700 1.24 1.41 1.61 0.97 1.27 0.87 100 1.22 1.07 1.39 132 21.1
NHS Wolverhampton 256,600 1.23 1.54 1.15 1.38 1.24 1.05 117 1.26 1.10 1.44 132 32.0
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Table 1.3. Continued
UK area CCG/HB
Total
population
(2016)
2011
O/E
2012
O/E
2013
O/E
2014
O/E
2015
O/E
2016 2011–2016
%
non-
WhiteO/E
Crude
rate
pmp O/E LCL UCL
Crude
rate
pmpa
Derbyshire
and
Notting-
hamshire
NHS Erewash 96,700 1.15 1.33 1.30 0.61 1.08 0.92 114 1.06 0.84 1.34 122 3.2
NHS Hardwick 111,400 0.70 0.85 0.76 0.85 0.82 0.55 72 0.75 0.59 0.97 93 1.8
NHS Mansﬁeld & Ashﬁeld 197,900 0.75 0.83 0.81 1.02 0.81 0.65 81 0.81 0.68 0.98 94 2.5
NHS Newark & Sherwood 119,700 1.29 0.93 0.49 0.72 0.62 0.76 100 0.79 0.63 1.00 99 2.4
NHS North Derbyshire 273,200 0.94 0.78 0.76 0.66 0.61 0.75 102 0.75 0.64 0.87 96 2.5
NHS Nottingham City 325,300 1.11 1.24 1.36 1.32 1.63 1.41 126 1.35 1.18 1.54 114 28.5
NHS Nottingham North & East 150,300 0.85 0.72 0.70 0.55 0.79 0.95 120 0.76 0.61 0.95 90 6.2
NHS Nottingham West 112,700 0.55 1.10 1.30 0.87 0.83 0.90 115 0.92 0.74 1.16 111 7.3
NHS Rushcliffe 115,200 1.16 0.38 1.04 0.42 0.20 0.81 104 0.66 0.51 0.86 80 6.9
NHS Southern Derbyshire 527,400 1.03 1.13 0.87 0.99 0.79 1.05 125 0.97 0.88 1.08 109 11.0
East Anglia NHS Cambridgeshire and
Peterboroughc
884,600 0.90 0.66 1.05 0.78 0.85 0.76 0.95 89 9.5
NHS Great Yarmouth &
Waveney
215,700 1.17 0.97 0.95 0.79 1.18 1.06 148 1.02 0.88 1.18 134 2.7
NHS Ipswich and East Suffolkb 401,000 0.62 0.89 0.91 0.72 1.06 0.77 102 0.83 0.74 0.94 104 5.6
NHS North Norfolkb 171,900 0.55 0.76 0.82 0.89 0.96 0.75 116 0.79 0.66 0.95 116 1.5
NHS Norwichb 216,800 1.09 0.96 0.80 0.84 0.92 0.69 78 0.88 0.74 1.05 95 7.3
NHS South Norfolkc 229,900 1.00 0.75 0.97 0.62 0.83 0.68 1.02 104 2.6
NHS West Norfolkc 175,100 0.63 0.67 0.61 0.86 0.70 0.55 0.89 91 2.6
NHS West Suffolkc 227,800 0.70 0.89 0.82 0.60 0.75 0.60 0.93 88 4.6
Essex NHS Basildon and Brentwood 259,800 1.04 1.26 0.94 0.99 1.07 1.11 131 1.07 0.92 1.23 118 7.1
NHS Castle Point, Rayleigh
and Rochford
175,400 0.75 0.70 1.18 0.73 0.90 0.87 120 0.86 0.71 1.03 111 3.0
NHS Mid Essexb 388,400 0.98 0.81 0.72 0.87 0.69 0.73 93 0.80 0.70 0.91 94 4.4
NHS North East Essexb 329,200 1.24 0.95 0.85 1.11 0.74 0.79 103 0.94 0.83 1.07 115 5.5
NHS Southend 179,800 0.84 0.94 1.07 0.72 1.01 1.29 156 0.98 0.82 1.17 111 8.4
NHS Thurrock 167,000 1.19 0.78 0.96 1.15 1.09 0.64 66 0.97 0.79 1.18 94 14.1
NHS West Essexb 302,500 0.73 1.19 1.04 1.10 0.94 0.89 106 0.98 0.85 1.12 110 8.2
Hertfordshire
and the
South Midlands
NHS Bedfordshire 447,700 0.72 0.95 0.98 0.93 0.81 1.03 121 0.90 0.80 1.02 100 11.2
NHS Corby 68,200 1.11 0.78 0.61 1.01 1.64 1.38 147 1.10 0.82 1.48 110 4.5
NHS East and North
Hertfordshire
565,700 1.04 0.70 1.09 1.03 1.04 0.97 111 0.98 0.88 1.09 105 10.4
NHS Herts Valleys 591,800 0.78 0.88 0.91 1.11 0.83 1.00 113 0.92 0.83 1.02 98 14.6
NHS Luton 216,800 1.38 1.21 1.98 1.52 1.30 1.85 175 1.54 1.33 1.79 138 45.3
NHS Milton Keynes 270,500 0.91 1.10 0.87 1.16 1.21 1.33 137 1.11 0.95 1.28 107 19.6
NHS Nene 648,600 0.88 1.06 0.96 0.90 0.80 0.84 99 0.90 0.82 1.00 100 9.1
Leicestershire
and
Lincolnshire
NHS East Leicestershire and
Rutland
328,600 0.72 0.97 0.90 0.77 0.90 0.77 100 0.84 0.73 0.96 103 9.8
NHS Leicester City 348,300 1.80 1.62 1.68 1.20 1.49 2.13 195 1.65 1.48 1.85 143 49.5
NHS Lincolnshire East 233,400 0.89 0.75 1.09 0.57 0.75 0.84 124 0.81 0.69 0.95 113 2.0
NHS Lincolnshire West 236,900 0.73 0.42 0.79 0.60 0.64 0.58 72 0.63 0.52 0.76 73 3.0
NHS South Lincolnshireb 147,800 0.96 0.90 0.66 0.67 0.89 0.85 115 0.82 0.67 1.00 105 2.3
NHS South West Lincolnshire 125,200 0.95 0.67 0.85 0.49 0.53 0.48 64 0.65 0.51 0.84 83 2.3
NHS West Leicestershire 393,000 0.89 0.51 0.80 0.97 0.61 0.85 104 0.77 0.68 0.88 89 6.9
Shropshire
and
Staffordshire
NHS Cannock Chase 135,100 1.15 0.80 1.17 0.80 0.88 1.07 133 0.98 0.80 1.20 115 2.4
NHS East Staffordshire 126,400 0.88 0.73 1.13 0.87 0.57 0.58 71 0.79 0.62 0.99 91 9.0
NHS North Staffordshire 218,300 1.11 0.59 0.96 1.01 1.03 1.11 147 0.97 0.83 1.14 121 3.5
NHS Shropshire 313,400 0.97 0.75 1.03 0.90 0.86 0.80 112 0.88 0.77 1.01 116 2.0
NHS South East Staffs and
Seisdon and Peninsular
225,200 0.99 0.72 0.63 0.76 0.73 0.84 111 0.78 0.65 0.92 97 3.6
NHS Stafford and Surrounds 154,000 0.82 0.92 0.84 0.84 1.28 1.15 156 0.98 0.82 1.18 126 4.7
NHS Stoke on Trent 261,400 1.06 0.87 1.10 1.45 1.12 1.13 130 1.13 0.98 1.30 122 11.0
NHS Telford & Wrekin 173,000 1.09 1.20 1.22 1.26 1.35 0.96 110 1.18 1.00 1.40 127 7.3
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Table 1.3. Continued
UK area CCG/HB
Total
population
(2016)
2011
O/E
2012
O/E
2013
O/E
2014
O/E
2015
O/E
2016 2011–2016
%
non-
WhiteO/E
Crude
rate
pmp O/E LCL UCL
Crude
rate
pmpa
London NHS Barking & Dagenham 206,500 1.65 2.03 1.60 1.94 1.91 1.69 140 1.80 1.56 2.09 141 41.7
NHS Barnet 386,100 1.41 1.46 1.23 1.29 1.41 1.27 130 1.34 1.20 1.50 129 35.9
NHS Camden 246,200 1.11 1.06 1.32 1.16 1.28 0.99 93 1.15 0.98 1.35 103 33.7
NHS City and Hackney 282,900 1.68 2.02 1.83 2.11 1.13 1.84 148 1.76 1.55 2.01 134 44.6
NHS Enﬁeld 331,400 1.98 1.59 1.58 1.53 1.55 1.59 157 1.63 1.46 1.83 151 39.0
NHS Haringey 278,500 1.69 2.27 2.21 1.64 1.56 1.94 172 1.88 1.66 2.12 157 39.5
NHS Havering 252,800 1.20 1.04 0.83 0.92 1.08 0.78 91 0.97 0.83 1.13 106 12.3
NHS Islington 232,900 1.53 2.05 1.44 1.11 1.60 1.06 90 1.46 1.25 1.70 117 31.8
NHS Newham 341,000 2.12 1.86 2.14 2.24 2.31 2.44 191 2.19 1.97 2.44 161 71.0
NHS Redbridge 299,200 1.38 2.15 1.98 1.45 1.45 1.73 167 1.68 1.50 1.90 153 57.5
NHS Tower Hamlets 304,900 1.61 1.82 2.02 2.26 2.33 1.84 134 1.99 1.76 2.25 137 54.8
NHS Waltham Forest 275,800 1.81 1.26 1.62 2.08 1.70 1.51 138 1.66 1.47 1.89 143 47.8
NHS Brent 328,300 2.08 2.43 1.95 2.51 2.23 2.02 195 2.20 1.99 2.43 200 63.7
NHS Central London
(Westminster)
178,400 1.29 1.17 1.37 1.08 0.97 1.09 112 1.16 0.97 1.38 112 36.2
NHS Ealing 343,200 1.91 2.26 1.68 1.78 2.25 1.77 175 1.94 1.76 2.15 181 51.0
NHS Hammersmith and
Fulham
179,700 1.43 1.49 0.99 1.44 1.13 1.80 167 1.38 1.16 1.64 121 31.9
NHS Harrow 248,800 2.23 1.59 1.06 1.54 1.43 1.70 185 1.59 1.40 1.80 162 57.8
NHS Hillingdon 302,500 1.46 1.50 1.42 1.00 1.08 1.16 116 1.26 1.10 1.44 118 39.4
NHS Hounslow 271,100 1.83 1.73 2.02 1.28 1.29 1.65 159 1.62 1.43 1.84 147 48.6
NHS West London
(Kensington and Chelsea,
Queen’s Park and Paddington)
226,000 1.20 0.91 0.98 1.50 0.67 1.23 128 1.08 0.92 1.27 106 33.4
NHS Bexley 244,800 1.17 0.87 1.01 1.11 1.24 1.65 184 1.19 1.03 1.37 124 18.1
NHS Bromley 326,900 0.69 0.72 0.85 0.99 1.50 0.82 95 0.94 0.82 1.08 102 15.7
NHS Croydon 382,300 1.26 2.00 1.95 1.79 1.93 1.64 167 1.76 1.60 1.95 169 44.9
NHS Greenwich 279,800 1.03 1.15 2.38 1.23 1.68 1.62 147 1.52 1.33 1.74 130 37.5
NHS Kingston 176,100 0.96 1.08 1.11 1.11 0.78 0.96 97 1.00 0.82 1.21 95 25.5
NHS Lambeth 327,900 1.76 1.68 1.39 1.87 1.95 1.38 116 1.67 1.48 1.89 132 42.9
NHS Lewisham 301,900 1.78 1.85 1.47 1.52 1.48 1.31 116 1.56 1.37 1.77 130 46.5
NHS Merton 205,000 1.57 1.78 1.30 1.44 1.61 1.73 171 1.57 1.36 1.82 146 35.1
NHS Richmond 195,800 0.69 0.79 0.98 0.78 0.60 0.65 71 0.74 0.61 0.92 77 14.0
NHS Southwark 313,200 1.96 1.74 2.23 1.82 1.83 1.69 144 1.88 1.67 2.11 150 45.8
NHS Sutton 202,200 1.30 1.54 0.80 1.66 1.40 1.41 153 1.36 1.17 1.58 138 21.4
NHS Wandsworth 316,100 1.23 1.39 0.96 1.56 1.77 1.38 120 1.39 1.22 1.59 114 28.6
Bath,
Gloucestershire,
Swindon
and Wiltshire
NHS Bath and North East
Somerset
187,800 0.56 0.92 0.95 0.66 0.59 0.73 85 0.73 0.60 0.90 81 5.4
NHS Gloucestershire 623,100 0.88 1.17 0.70 0.92 0.87 0.86 111 0.90 0.81 0.99 109 4.6
NHS Swindon 223,600 1.14 1.22 0.92 1.16 1.15 1.08 121 1.11 0.95 1.30 117 10.0
NHS Wiltshire 488,400 0.64 0.47 0.77 0.81 0.69 0.83 106 0.71 0.62 0.80 85 3.4
Bristol, North
Somerset,
Somerset and
South
Gloucestershire
NHS Bristol 454,200 1.44 1.26 1.38 1.16 1.20 1.30 125 1.29 1.15 1.44 117 16.0
NHS North Somerset 211,700 0.87 1.02 1.04 1.01 0.79 0.77 104 0.91 0.78 1.07 117 2.7
NHS Somerset 549,400 0.84 0.67 0.55 0.88 0.66 0.86 118 0.75 0.67 0.83 96 2.0
NHS South Gloucestershire 277,600 0.61 0.81 1.15 0.68 0.74 0.81 97 0.80 0.68 0.94 91 5.0
Devon,
Cornwall and
Isles of Scilly
NHS Kernow 556,000 0.81 0.95 0.88 0.79 1.01 0.90 126 0.89 0.81 0.99 117 1.8
NHS North, East, West Devon 898,000 0.92 1.00 0.84 0.92 0.90 0.87 115 0.91 0.84 0.98 112 3.0
NHS South Devon and Torbay 279,900 0.90 1.08 1.00 0.87 0.88 0.98 143 0.95 0.83 1.08 130 2.1
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Table 1.3. Continued
UK area CCG/HB
Total
population
(2016)
2011
O/E
2012
O/E
2013
O/E
2014
O/E
2015
O/E
2016 2011–2016
%
non-
WhiteO/E
Crude
rate
pmp O/E LCL UCL
Crude
rate
pmpa
Kent and
Medway
NHS Ashford 126,200 0.83 1.26 1.09 0.96 0.85 0.99 119 0.99 0.80 1.23 112 6.3
NHS Canterbury and Coastal 210,500 0.83 0.57 0.94 1.16 0.88 1.00 124 0.90 0.76 1.07 105 5.9
NHS Dartford, Gravesham and
Swanley
260,600 0.87 0.98 1.47 0.93 0.96 1.13 130 1.06 0.91 1.22 114 13.0
NHS Medway 278,500 0.90 0.81 1.08 0.92 1.17 0.59 65 0.91 0.78 1.07 94 10.4
NHS South Kent Coast 207,600 1.01 0.56 0.74 1.00 0.88 1.07 145 0.88 0.75 1.04 112 4.5
NHS Swale 114,800 0.59 1.33 0.81 1.15 0.88 1.18 139 0.99 0.79 1.24 110 3.8
NHS Thanet 140,700 0.86 1.04 1.55 1.01 0.70 0.86 114 1.00 0.82 1.21 123 4.5
NHS West Kent 481,600 0.82 0.62 0.70 0.91 0.80 0.80 98 0.78 0.69 0.88 89 4.9
Surrey and
Sussex
NHS Brighton & Hove 289,200 0.92 1.16 0.79 1.06 1.05 1.40 142 1.07 0.92 1.24 102 10.9
NHS Coastal West Sussex 498,900 0.64 0.80 0.78 1.02 0.88 0.96 136 0.85 0.77 0.95 114 3.8
NHS Crawley 111,400 0.50 0.80 1.07 1.29 0.70 1.59 162 1.00 0.79 1.28 96 20.1
NHS East Surrey 183,700 0.74 1.25 0.91 0.82 1.46 0.83 98 1.01 0.84 1.20 112 8.3
NHS Eastbourne, Hailsham
and Seaford
189,500 0.84 1.04 1.18 0.73 1.06 0.85 121 0.95 0.81 1.12 128 4.4
NHS Guildford and Waverley 207,800 0.74 1.16 0.54 0.77 0.94 0.58 67 0.79 0.65 0.95 87 7.2
NHS Hastings & Rother 185,800 0.96 0.73 1.22 0.63 0.99 0.72 102 0.87 0.73 1.04 116 4.6
NHS High Weald Lewes
Havens
172,600 0.68 0.91 0.61 0.97 0.84 0.89 122 0.82 0.68 0.99 105 3.1
NHS Horsham and Mid Sussex 233,500 0.78 0.51 0.76 0.82 0.51 0.76 94 0.69 0.57 0.83 81 4.9
NHS North West Surrey 344,600 1.31 0.91 0.94 1.22 0.87 1.20 142 1.08 0.95 1.22 120 12.5
NHS Surrey Downs 288,200 0.97 0.90 1.02 0.94 0.84 0.82 104 0.91 0.79 1.05 109 9.1
NHS Surrey Heath 96,700 0.77 0.76 0.46 0.44 0.92 0.50 62 0.64 0.47 0.86 74 9.3
Thames Valley NHS Aylesbury Vale 211,400 1.01 0.73 0.67 0.80 0.72 1.21 142 0.86 0.72 1.03 95 9.7
NHS Bracknell and Ascot 137,700 0.76 0.37 1.24 0.96 0.79 0.99 109 0.86 0.68 1.08 88 9.5
NHS Chiltern 325,900 0.69 0.74 1.00 0.78 0.77 0.73 89 0.78 0.68 0.91 90 15.8
NHS Newbury and District 107,100 0.62 0.62 1.03 0.89 0.70 1.01 121 0.82 0.63 1.05 92 4.4
NHS North & West Reading 100,300 0.95 0.94 0.64 0.95 0.90 0.91 110 0.88 0.68 1.13 100 10.4
NHS Oxfordshire 668,700 1.01 0.98 0.88 0.83 0.81 0.75 87 0.87 0.79 0.96 95 9.3
NHS Slough 147,200 2.20 1.74 1.78 1.69 1.91 1.62 143 1.82 1.54 2.16 151 54.3
NHS South Reading 112,000 1.16 1.17 2.38 1.51 0.72 1.34 116 1.37 1.09 1.72 112 30.5
NHS Windsor, Ascot and
Maidenhead
142,900 1.24 0.62 1.33 1.20 0.66 0.97 112 1.00 0.82 1.22 108 14.7
NHS Wokingham 161,900 1.31 0.47 0.81 0.76 0.57 0.73 86 0.77 0.62 0.95 85 11.6
Wessex NHS Dorset 771,900 0.73 0.71 0.73 0.71 0.61 0.57 79 0.67 0.61 0.74 87 4.0
NHS Fareham and Gosport 200,800 0.78 0.78 0.97 1.07 0.87 0.88 115 0.90 0.76 1.06 110 3.4
NHS Isle of Wight 139,800 0.77 0.87 1.22 0.85 0.67 0.58 86 0.82 0.67 1.00 114 2.7
NHS North East Hampshire
and Farnham
210,500 0.84 1.16 1.17 0.85 0.97 0.86 100 0.97 0.82 1.15 106 9.7
NHS North Hampshire 221,900 0.69 0.47 0.71 1.02 0.75 0.53 63 0.70 0.57 0.84 78 6.4
NHS Portsmouth 214,800 1.31 1.10 1.12 0.96 1.06 1.07 107 1.10 0.93 1.30 104 11.6
NHS South Eastern Hampshire 212,300 0.76 0.63 0.96 1.09 0.69 0.63 85 0.79 0.67 0.94 100 3.1
NHS Southampton 254,300 1.15 0.88 0.63 0.98 0.93 0.94 90 0.92 0.77 1.09 83 14.1
NHS West Hampshire 558,300 0.67 0.62 0.66 0.76 0.57 0.55 73 0.64 0.57 0.72 80 3.9
Wales Betsi Cadwaladr University 695,800 0.84 1.01 0.88 1.08 1.06 0.98 131 0.98 0.90 1.07 122 2.5
Powys Teaching 132,200 1.28 1.27 0.73 0.58 0.96 0.92 136 0.95 0.79 1.15 132 1.6
Hywel Dda 383,700 1.25 0.92 1.08 1.18 1.05 0.78 107 1.04 0.93 1.16 135 2.2
Abertawe Bro Morgannwg
University
529,300 1.18 1.45 1.04 0.94 1.20 1.16 144 1.16 1.05 1.27 135 3.9
Cwm Taf 298,100 1.46 0.91 1.13 1.13 0.97 0.98 117 1.09 0.96 1.24 124 2.6
Aneurin Bevan 584,100 1.21 1.18 1.05 1.16 0.97 0.91 113 1.07 0.98 1.18 126 3.9
Cardiff and Vale University 489,900 1.01 0.99 1.11 0.93 0.93 1.15 122 1.02 0.91 1.14 103 12.2
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between areas, with ratios ranging from 0.52 to 2.53 (IQR
0.82, 1.09). From the analysis using all six years (where
available), out of a total of 233 areas, 44 areas had notably
high ratios and 67 notably low. The crude rates ranged
from 70 pmp to 200 pmp (IQR 96 pmp, 121 pmp).
These rates and ratios are not adjusted for population
ethnicity, which correlates strongly with incidence at
CCG/HB level (ﬁgure 1.3).
Centre level
The number of new patients starting RRT at each
renal centre from 2011 to 2016 is shown in table 1.4.
The table also shows centre level incidence rates (per
million population) for 2016. For most centres there
was a lot of variability in the numbers of incident
patients from one year to the next, making it hard to
see any underlying trend. Variation incorporates chance
ﬂuctuation, the introduction of new centres, changes in
catchment populations and completeness of reporting.
Trends reﬂect changes in incidence of ERF (under-
lying disease prevalence, recognition and survival from
comorbidity), and practice changes such as an emphasis
Table 1.3. Continued
UK area CCG/HB
Total
population
(2016)
2011
O/E
2012
O/E
2013
O/E
2014
O/E
2015
O/E
2016 2011–2016
%
non-
WhiteO/E
Crude
rate
pmp O/E LCL UCL
Crude
rate
pmpa
Scotland Ayrshire and Arran 370,600 0.83 0.96 1.00 0.80 0.90 1.21 162 0.95 0.85 1.07 120 1.2
Borders 114,500 0.56 0.56 0.47 0.57 0.67 0.31 44 0.52 0.39 0.69 70 1.3
Dumfries and Galloway 149,500 0.58 1.05 0.41 1.20 0.64 0.51 74 0.73 0.59 0.90 99 1.2
Fife 370,300 1.17 0.87 1.01 0.91 1.04 0.71 89 0.95 0.84 1.07 113 2.4
Forth Valley 304,500 0.82 0.88 1.00 0.92 1.01 0.61 76 0.87 0.75 1.01 101 2.2
Grampian 588,100 0.83 0.86 0.91 0.76 0.88 0.80 95 0.84 0.75 0.94 94 4.0
Greater Glasgow and Clyde 1,161,400 1.11 1.13 0.93 0.90 1.14 1.09 124 1.05 0.98 1.12 113 7.3
Highland 321,900 0.52 0.62 0.68 0.52 0.93 0.59 81 0.65 0.55 0.75 83 1.3
Lanarkshire 656,500 0.84 1.08 0.93 0.89 0.94 0.97 117 0.94 0.86 1.04 107 2.0
Lothian 880,000 0.71 0.74 0.60 0.75 0.70 0.72 81 0.70 0.64 0.78 74 5.6
Orkney 21,900 0.00 1.85 0.72 0.00 1.62 0.00 0 0.69 0.39 1.22 92 0.7
Shetland 23,200 0.78 0.00 0.75 1.06 1.02 0.68 86 0.73 0.41 1.28 86 1.5
Tayside 415,500 1.20 0.68 0.87 0.96 0.95 0.86 111 0.92 0.82 1.03 111 3.2
Western Isles 26,900 0.00 0.00 0.85 1.60 1.79 1.03 149 0.91 0.59 1.42 124 0.9
Northern
Ireland
Belfast 354,700 1.08 1.71 1.17 0.88 1.24 1.46 155 1.25 1.11 1.41 125 3.2
Northern 473,100 1.24 1.12 1.03 1.01 0.93 1.09 125 1.07 0.96 1.19 115 1.2
Southern 377,200 1.27 0.86 0.83 0.76 0.88 0.78 82 0.89 0.78 1.02 88 1.2
South Eastern 356,700 0.92 0.80 0.91 0.76 1.27 1.02 121 0.95 0.84 1.09 106 1.3
Western 300,400 0.97 0.59 0.97 1.05 1.15 1.10 120 0.98 0.85 1.13 100 1.0
a – per year
bCCGs where between 5% and 15% of the incident RRT population from 2011 to 2014 were incident patients of the Cambridge renal centre. In
these CCGs the rates/ratios for 2015 and 2016 and for the combined years 2011–2016 are likely to be underestimated
cCCGs where .15% of the incident RRT population from 2011 to 2014 were incident patients of the Cambridge renal centre. These have not
been included in the analysis for 2015 or 2016 but are included for 2011–2014 (and the combined years analysis for these areas uses only four
years (2011–2014))
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Table 1.4. Number of patients starting RRT by renal centre 2011–2016
Year Estimated catchment
population
2016
crude
Centre 2011 2012 2013 2014 2015 2016 (millions)a rate pmpb (95% CI)
England
B Heart 113 101 100 100 123 135 0.74 183 (152–214)
B QEH 213 208 200 249 245 238 1.70 140 (122–158)
Basldn 44 53 34 45 48 40 0.42 96 (67–126)
Bradfd 60 71 63 83 91 86 0.65 132 (104–160)
Brightn 119 132 139 148 144 150 1.30 116 (97–134)
Bristol 141 149 174 149 146 155 1.44 108 (91–125)
Cambc 122 123 136 126 175c 120c 1.16 104 (85–122)
Carlis 27 19 42 37 46 35 0.32 109 (73–145)
Carsh 207 244 229 265 260 246 1.91 129 (113–145)
Chelms 47 46 47 55 51 53 0.51 104 (76–132)
Colchr 44 29 29 38 28 30 0.30 100 (64–136)
Covnt 110 114 90 126 111 128 0.89 143 (119–168)
Derby 74 80 74 77 64 86 0.70 122 (97–148)
Donc 43 40 61 54 39 62 0.41 151 (114–189)
Dorset 79 73 73 78 75 70 0.86 81 (62–100)
Dudley 43 56 52 42 51 53 0.44 120 (88–152)
Exeter 112 134 100 143 137 143 1.09 131 (110–153)
Glouc 58 75 53 74 72 66 0.59 112 (85–140)
Hull 108 94 90 98 121 93 1.02 91 (73–110)
Ipswi 29 44 40 34 67 42 0.40 105 (73–137)
Kent 120 114 143 148 143 141 1.22 115 (96–134)
L Barts 250 264 283 302 311 297 1.83 162 (144–181)
L Guys 121 130 134 159 179 169 1.08 156 (133–180)
L Kings 137 123 166 148 180 152 1.17 130 (109–150)
L Rfree 220 232 224 230 239 238 1.52 157 (137–177)
L St.G 72 95 85 92 114 94 0.80 118 (94–142)
L West 364 354 303 355 337 385 2.40 160 (144–177)
Leeds 153 151 183 169 147 166 1.67 99 (84–115)
Leic 266 235 288 251 270 324 2.44 133 (119–147)
Liv Ain 58 63 65 65 61 53 0.48 110 (80–139)
Liv Roy 111 104 93 136 141 111 1.00 111 (90–132)
M RI 154 161 198 164 198 219 1.53 143 (124–162)
Middlbr 100 119 110 102 134 101 1.00 101 (81–120)
Newc 98 102 92 109 125 135 1.12 120 (100–141)
Norwch 88 75 78 77 112 97 0.79 123 (99–148)
Nottm 115 100 116 111 120 120 1.09 110 (91–130)
Oxford 176 170 164 188 195 218 1.69 129 (112–146)
Plymth 60 54 65 54 53 63 0.47 134 (101–167)
Ports 187 159 193 230 200 191 2.02 94 (81–108)
Prestn 138 146 154 164 163 133 1.49 89 (74–104)
Redng 103 72 117 104 87 96 0.91 105 (84–127)
Salford 131 134 116 161 173 188 1.49 126 (108–144)
Sheff 134 156 136 164 146 151 1.37 110 (93–128)
Shrew 61 58 60 65 62 58 0.50 116 (86–146)
Stevng 110 109 156 150 136 165 1.20 137 (116–158)
Sthend 29 26 42 30 35 47 0.32 148 (106–191)
Stoke 91 74 103 117 116 107 0.89 120 (97–143)
Sund 57 71 51 63 63 94 0.62 152 (121–183)
Truro 39 49 47 40 70 50 0.41 121 (87–155)
Wirral 58 46 65 55 64 69 0.57 121 (92–149)
Wolve 78 88 93 74 85 64 0.67 96 (72–119)
York 53 55 37 64 61 72 0.49 146 (112–180)
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on pre-emptive transplantation or the introduction of
conservative care programmes. Analysis of data from
patients with chronic kidney disease (CKD) stage 5
who are not receiving RRT is required to explore these
underlying mechanisms.
The number of people starting RRT in the UK
increased between 2011 and 2016, with an overall rise
of 14.0% over these six years.
2. Demographics and clinical characteristics of
patients starting RRT
Methods
Age, sex, primary renal disease, ethnic origin and treatment
modality were examined for patients starting RRT.
Crude CCG/HB incidence rates were calculated for the over
75 year age group. These are per million age related population
(pmarp), i.e. the number of incident patients over 75 years old
divided by the population over 75 years old.
A mixture of old and new (2012) ERA-EDTA codes for
primary diagnoses [2] were received from centres. For those
people without an old code, new codes (where available) were
converted to old codes using the mapping available on the ERA-
EDTA website. As recommended in the notes for users in the
ERA-EDTA’s primary renal diagnosis (PRD) code list document,
this mapping is provided for guidance only and has not been vali-
dated. These codes were grouped into the same eight categories as
in previous reports, the details are given in appendix H: Ethnicity
and ERA-EDTA Coding (www.renalreg.org).
Most centres electronically upload ethnicity coding to their
renal information technology (IT) system from the hospital
Patient Administration System (PAS). Ethnicity coding in these
PAS systems was based on self-reported ethnicity. For the
Table 1.4. Continued
Year Estimated catchment
population
2016
crude
Centre 2011 2012 2013 2014 2015 2016 (millions)a rate pmpb (95% CI)
N Ireland
Antrim 29 25 29 35 36 41 0.29 139 (97–182)
Belfast 68 97 72 65 94 95 0.64 149 (119–179)
Newry 36 17 23 20 28 25 0.26 96 (58–133)
Ulster 36 28 30 23 33 30 0.27 113 (72–153)
West NI 35 22 30 35 39 35 0.35 99 (67–132)
Scotland
Abrdn 50 53 58 53 66 52 0.60 87 (63–110)
Airdrie 48 60 51 50 64 62 0.55 112 (84–140)
D & Gall 10 18 8 22 12 11 0.15 74 (30–118)
Dundee 59 38 42 50 46 45 0.46 97 (69–126)
Edinb 76 82 72 90 97 87 0.96 90 (71–109)
Glasgw 177 184 174 173 221 198 1.62 122 (105–139)
Inverns 12 16 21 22 35 19 0.27 70 (39–102)
Klmarnk 33 40 40 34 39 53 0.36 147 (107–186)
Krkcldy 43 30 38 36 44 32 0.32 101 (66–136)
Wales
Bangor 20 21 24 22 29 25 0.22 115 (70–160)
Cardff 186 169 171 168 160 161 1.42 113 (96–131)
Clwyd 17 22 17 32 28 16 0.19 84 (43–126)
Swanse 118 118 109 120 136 124 0.89 140 (115–165)
Wrexm 26 34 35 42 45 49 0.24 204 (147–261)
% increase since 2011
England 5,725 5,774 5,986 6,362 6,614 6,599 15.3
N Ireland 204 189 184 178 230 226 10.8
Scotland 508 521 504 530 624 559 10.0
Wales 367 364 356 384 398 375 2.2
UK 6,804 6,848 7,030 7,454 7,866 7,759 14.0
aSee appendix E for details of estimation of catchment populations
bpmp – per million population
cCambridge was unable to submit patient level data for 2015 or 2016 but provided the UKRR with information allowing their incident
numbers for 2015 and 2016 to be estimated. These numbers have been used here and in table 1.2 but not elsewhere in this chapter
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remaining centres, ethnicity coding was performed by clinical staff
and recorded directly into the renal IT system (using a variety of
coding systems). Data on ethnic origin were grouped into
White, South Asian, Black, Chinese or Other. The details of
regrouping of the PAS codes into the above ethnic categories are
provided in appendix H: Ethnicity and ERA-EDTA Coding
(www.renalreg.org). Chi-squared, Fisher’s exact, ANOVA and
Kruskal Wallis tests were used as appropriate.
Data were withheld from some tables due to small numbers of
patients in a category that increase the possibility of identifying
patients. Primary suppression is the withholding of information
from risky cells for publication, which means that their value is
not shown in the table but replaced by a symbol such as ‘×’ to
indicate the suppression. According to the deﬁnition of a risky
cell, in frequency count tables all cells containing small counts
and in tables of magnitudes all cells containing small counts or
presenting a case of dominance have to be primary suppressed.
To reach the desired protection for risky cells, it is necessary to
suppress additional non-risky cells, which is called complementary
(secondary) suppression. The pattern of complementary suppres-
sed cells has to be carefully chosen to provide the desired level of
ambiguity for the risky cells with the least amount of suppressed
information.
Estimated glomerular ﬁltration rate (eGFR) at the start of RRT
was studied amongst patients with eGFR data within 14 days
before the start of RRT. The eGFR was calculated using the
CKD-EPI equation [3]. The abbreviated four variable MDRD
study equation was also used to allow comparison with values pub-
lished in previous years. For the purpose of the eGFR calculation,
patients who had missing ethnicity but a valid serum creatinine
measurement were classed as White. The eGFR values were log
transformed due to their skewed distribution and geometric
means calculated.
Results
Incidence rates appear to have plateaued in the over 65
age group, but continued to rise amongst individuals
between 45 and 64 years of age (ﬁgure 1.4). Figure 1.5
shows RRT incidence rates for 2016 by age group and
sex. The peak rate was in the 80–84 age group for men
and 75–79 for women. Figure 1.6 shows the numbers of
people starting HD and PD by age group. The age
group with the highest number of HD and PD starters
was 65–74. Haemodialysis was used proportionately
more, with increasing age above the age of 35.
Age
In 2016, the median age of patients starting RRT was
64.3 years (table 1.5) and this has changed little over
recent years. Per modality, the median age at start was
66.8 years for patients starting on HD, 60.5 for patients
starting on PD and 50.5 for those having a pre-emptive
transplant (table 1.6). The median age at start, of non-
White patients, was 58.7, considerably lower than that
for White patients (66.2 years) reﬂecting differences in
CKD frequency and progression and the younger age
distribution of ethnic minority populations in general,
compared with the White population (in the 2011 census
data for England and Wales, 5.3% of ethnic minorities
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were over 65 years old compared to 18.3% of Whites) [4].
The median age of new patients with diabetes was similar
to the overall median and has not varied greatly over
recent years.
There were large differences between centres in the
median age of incident patients (ﬁgure 1.7). This is likely
to reﬂect differences in the age and ethnic structure of the
catchment populations (for which these data were not
adjusted) along with chance, particularly in centres with
small numbers of incident patients. Nevertheless, true
practice variation may exist. The median age of patients
starting treatment at transplant centres was 62.8 years
(IQR 50.3, 73.3) and at non-transplanting centres 66.0
years (IQR 52.7, 75.5).
Averaged over 2011–2016, crude CCG/HB incidence
rates in the over 75 year age group varied from 57 per
million age related population (pmarp) in Borders
to 1,048 pmarp in NHS Brent (IQR 259 pmarp,
400 pmarp, data not shown). The variation between
CCG/HBs seen in the over 75 year age group was much
greater than the variation seen in the overall analysis.
Some of this difference is likely to be due to the smaller
numbers included in the over 75 analysis.
Sex
More men than women started RRT in every age
group and this sex effect appeared to increase with age
(ﬁgure 1.8). The overall breakdown was 62.9% male,
37.1% female.
Table 1.5. Median, inter-quartile range and 90% range of the
age of patients starting renal replacement therapy in 2016 by
country
Country Median IQR 90% range
England 64.3 (51.5–74.5) (31.4–84.1)
N Ireland 66.0 (51.3–74.2) (34.5–82.9)
Scotland 62.4 (49.9–72.9) (32.4–81.9)
Wales 66.3 (55.4–76.5) (34.3–85.8)
UK 64.3 (51.6–74.5) (31.9–84.0)
IQR – interquartile range
Table 1.6. Median, inter-quartile range and 90% range of the
age of patients starting renal replacement therapy in 2016 by
initial treatment modality
Treatment Median IQR 90% range
HD 66.8 (54.7–76.0) (34.0–84.7)
PD 60.5 (47.3–72.0) (30.2–82.5)
Transplant 50.5 (41.1–60.3) (26.6–70.5)
IQR – interquartile range
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Ethnicity
As in previous reports, Scotland is not included in this
section as completeness of ethnicity data was low. Across
centres in England, Wales and Northern Ireland the
average completeness was 94.9% for 2016 incident
patients, similar to the 95.8% seen last year and the
94.8% the year before. Data completeness and the percen-
tage in minority ethnic groups are shown by centre in
table 1.7a. Table 1.7b shows the overall detailed ethnicity
breakdown for England, Wales and Northern Ireland.
Table 1.7a. Percentage of incident patients (2016) in minority ethnic groups (South Asian, Black, Chinese or Other) by centre
Centre
Percentage
with data
not available
N with
data
Percentage
non-White
England
B Heart 0.0 135 34
B QEH 3.8 229 40
Basldn 5.0 38 18
Bradfd 1.2 85 40
Brightn 10.7 134 *
Bristol 19.4 125 12
Carlis 2.9 34 *
Carsh 8.9 224 29
Chelms 0.0 53 *
Colchr 3.3 29 *
Covnt 3.1 124 19
Derby 1.2 85 11
Donc 0.0 62 *
Dorset 1.4 69 *
Dudley 0.0 53 25
Exeter 1.4 141 *
Glouc 1.5 65 *
Hull 2.2 91 *
Ipswi 7.1 39 26
Kent 2.1 138 *
L Barts 0.3 296 69
L Guys 5.3 160 43
L Kings 0.0 152 48
L Rfree 5.0 226 53
L St.G 14.9 80 54
L West 0.0 385 59
Leeds 0.6 165 25
Leic 9.0 295 23
Liv Ain 1.9 52 *
Liv Roy 2.7 108 11
M RI 4.1 210 30
Middlbr 2.0 99 *
Newc 0.0 135 *
Norwch 2.1 95 *
Centre
Percentage
with data
not available
N with
data
Percentage
non-White
Nottm 0.8 119 19
Oxford 20.2 174 20
Plymth 1.6 62 *
Ports 15.7 161 *
Prestn 0.0 133 16
Redng 15.6 81 23
Salford 3.2 182 21
Sheff 2.6 147 *
Shrew 3.4 56 *
Stevng 14.5 141 26
Sthend 0.0 47 19
Stoke 9.3 97 *
Sund 0.0 94 *
Truro 0.0 50 *
Wirral 2.9 67 *
Wolve 0.0 64 30
York 6.9 67 *
N Ireland
Antrim 0.0 41 *
Belfast 17.9 78 *
Newry 0.0 25 *
Ulster 0.0 30 *
West NI 2.9 34 *
Wales
Bangor 12.0 22 *
Cardff 3.7 155 *
Clwyd 18.8 13 *
Swanse 0.0 124 *
Wrexm 6.1 46 *
England 5.0 6,153 25
N Ireland 8.0 208 *
Wales 4.0 360 *
E, W & NI 5.1 6,721 23
*,10% in minority ethnic group
Table 1.7b. Percentage of incident RRT patients (2016) in different ethnic groups (England, Wales and Northern Ireland)
Country
% data not
available
N with
data
Percentage in each ethnic group
White South Asian Black Chinese Other
E, W & NI 5.1 6,721 76.8 12.1 7.4 0.5 3.2
E, W & NI – England, Wales, Northern Ireland
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Table 1.8a. Distribution of primary renal diagnosis by country in the 2012–2016 incident RRT cohort
Percentage
Centre
Percentage
with data
not available
N
with
data
Uncertain
aetiology Diabetes
Glomerulo-
nephritis
Hyper-
tension Other
Polycystic
kidney
Pyelo-
nephritis
Renal
vascular
disease
England
B Heart 2 546 16 37 10 9 14 4 7 3
B QEH 0 1,137 16 24 13 6 21 6 5 9
Basldn 3 213 6 30 18 7 12 4 8 15
Bradfd 0 394 18 29 15 8 15 5 5 5
Brightn 1 709 22 22 14 4 19 8 6 6
Bristol 5 733 13 24 14 5 20 10 8 7
Carlis 7 167 * 20 17 17 * 12 8 11
Carsh 58 521
Chelms 2 246 17 27 15 5 20 5 7 4
Colchr 2 56 32 34 * * * * * *
Covnt 7 530 14 23 15 12 14 5 7 10
Derby 1 377 11 32 18 2 17 6 7 6
Donc 1 254 21 20 14 10 20 5 6 5
Dorset 0 369 11 26 13 10 15 11 8 6
Dudley 1 252 25 21 11 7 25 6 * *
Exeter 1 651 10 23 14 9 18 7 7 13
Glouc 0 339 30 22 14 3 12 8 6 5
Hull 1 493 20 21 17 6 15 11 7 4
Ipswi 50 21
Kent 1 683 23 23 15 5 17 5 8 4
L Barts 8 1,342 13 36 11 10 15 5 8 3
L Guys 25 459
L Kings 0 769 10 36 10 18 13 4 5 3
L Rfree 3 1,123 11 32 12 9 23 4 4 6
L St.G 31 331
L West 0 1,734 11 40 13 3 17 6 5 5
Leeds 0 814 12 23 14 9 19 9 9 4
Leic 19 1,108 22 22 13 6 15 9 8 5
Liv Ain 0 307 15 22 15 10 15 5 8 11
Liv Roy 29 413
M RI 7 870 10 30 13 13 20 6 6 3
Middlbr 1 563 16 26 13 6 16 8 7 7
Newc 0 561 13 23 15 4 22 8 6 9
Norwch 2 429 26 20 16 4 17 7 6 5
Nottm 0 566 22 22 12 5 20 7 7 5
Oxford 3 905 13 28 16 6 17 9 6 5
Plymth 11 258 7 20 18 7 16 8 6 18
Ports 20 782 9 25 15 9 18 10 8 7
Prestn 1 756 13 25 15 11 16 6 8 6
Redng 1 470 18 30 13 3 18 6 6 6
Salford 27 564
Sheff 2 737 18 25 19 5 12 7 7 8
Shrew 3 293 22 24 10 4 22 5 6 6
Stevng 9 653 20 24 11 2 29 7 3 4
Sthend 1 178 19 19 15 6 19 10 7 6
Stoke 9 468 7 28 12 8 22 8 5 10
Sund 1 338 5 23 11 19 17 8 9 8
Truro 1 253 9 26 20 8 17 6 7 7
Wirral 11 266 7 32 9 14 25 5 3 5
Wolve 1 398 26 20 12 3 28 4 5 4
York 1 287 8 20 18 10 22 8 7 6
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Primary renal diagnosis
The breakdown of PRD by centre is shown for a
2012–2016 incident cohort in table 1.8a. The breakdown
by country is shown for 2016 incident patients in
table 1.8b. For completeness data for 2016 by centre see
the Introduction chapter of this report. Fifty-four centres
provided data on over 90% of incident patients and 31 of
these centres had 100% completeness. There was only a
small amount of missing data for Northern Ireland,
Scotland and Wales, whilst England had 12.5% missing.
The overall percentage missing was 11.1% and this was
similar in the under 65–year olds and those aged 65
and over (10.8% and 11.3% respectively). Eight centres
had missing PRD for more than 25% of incident
patients.
The UKRR continues to be concerned about centres
with apparently very high data completeness for PRD,
but also very high rates of ‘uncertain’ diagnoses (EDTA
code 00: chronic renal failure; aetiology uncertain). It is
accepted that there will inevitably be patients with uncer-
tain aetiology. The proportion of these patients will vary
between clinicians and centres in part because the diag-
nostic criteria of conditions such as hypertensive renal
disease permit subjectivity. Many of the new ERA-
Table 1.8a. Continued
Percentage
Centre
Percentage
with data
not available
N
with
data
Uncertain
aetiology Diabetes
Glomerulo-
nephritis
Hyper-
tension Other
Polycystic
kidney
Pyelo-
nephritis
Renal
vascular
disease
N Ireland
Antrim 0 166 33 27 10 * 17 3 7 *
Belfast 8 390 15 20 15 3 21 12 11 3
Newry 0 113 17 26 11 * 21 7 5 *
Ulster 0 144 12 27 10 12 16 4 7 13
West NI 0 161 6 25 12 11 19 5 13 9
Scotland
Abrdn 0 282 10 31 17 7 18 8 6 4
Airdrie 0 287 18 29 16 3 14 8 7 5
D & Gall 0 71 * 42 14 14 14 * * *
Dundee 0 221 12 22 14 9 24 9 5 5
Edinb 0 428 13 26 17 4 20 10 5 5
Glasgw 0 950 11 30 17 2 17 9 6 9
Inverns 1 112 20 19 14 * 25 10 6 *
Klmarnk 0 206 4 30 13 5 17 8 10 14
Krkcldy 7 168 16 24 14 * 17 5 6 *
Wales
Bangor 2 118 16 27 10 8 15 6 4 13
Cardff 0 828 22 26 18 2 12 9 5 6
Clwyd 11 102 17 27 12 11 21 * * *
Swanse 1 601 7 29 17 2 17 4 7 16
Wrexm 1 202 13 23 16 4 15 9 9 9
England 8 27,686 15 27 14 8 18 7 7 6
N Ireland 3 974 16 24 12 6 19 7 9 6
Scotland 0 2,725 12 28 16 4 18 8 6 8
Wales 1 1,851 16 27 17 3 15 7 6 10
UK 7 33,236 15 27 14 7 18 7 7 6
*values suppressed due to small numbers (primary or secondary suppression – see methods)
The percentage in each category has been calculated after excluding those patients with data not available
Blank cells – centres with .25% missing primary diagnoses, the percentages in the other diagnostic categories have not been calculated
For those centres judged to have high % uncertain aetiology for a year (arbitrarily deﬁned as .45%), their data has not been used for that
year
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EDTA codes allow clinicians to indicate the basis for the
diagnosis of the PRD (e.g. biopsy-proven, or not). Adop-
tion of these codes should reduce ‘uncertain’ PRD coding.
There was wide variation in all PRD codes between
centres.
The UK age distribution of PRDs is shown in table 1.9.
Diabetic nephropathy was the most common renal diag-
nosis overall and in all age groups except the under 35s
and those over 85. Glomerulonephritis and autosomal
dominant polycystic kidney disease (ADPKD) made up
much higher proportions of the younger than the older
incident cohorts, whilst patients with renal vascular
disease comprised a much higher percentage of the
older rather than the younger patients. Aetiological
uncertainty increased with age.
Table 1.10 shows the incidence rates for each PRD per
million population for the 2016 cohort. As there were
some missing data, the rates for at least some of the
diagnoses will be underestimates.
First established treatment modality
In 2016, the ﬁrst treatment recorded, irrespective of
any later change, was haemodialysis in 72.4% of patients,
peritoneal dialysis in 20.3% and pre-emptive transplant
in 7.4% (table 1.11). The percentage having a pre-emptive
transplant fell in 2015, however, about half of the appar-
ent drop was due to Cambridge (a transplant centre) not
being included in the data for 2015 or 2016. Table F.1.3 in
appendix F: Additional Data Tables for 2016 new and
existing patients gives the treatment breakdown at start
of RRT by centre.
Many patients undergo a period of HD before switches
to other modalities are, or can be, considered. The
modality in use at 90 days may be more representative
of the ﬁrst elective modality and is adopted for the
remainder of this section. For these analyses, the incident
cohort from 1 October 2015 to 30 September 2016 was
used so that follow up to 90 days was possible for all
patients. By 90 days, 4.0% of incident patients had died
Table 1.8b. Distribution of primary renal diagnosis by country in the 2016 incident RRT cohort
Percentage
Country
%
data not
available
N
with
data
Uncertain
aetiology Diabetes
Glomerulo-
nephritis
Hyper-
tension Other
Polycystic
kidney
Pyelo-
nephritis
Renal
vascular
disease
England 12.5 5,669 14.9 28.7 13.0 7.0 17.0 6.9 6.4 6.1
N Ireland 4.0 217 16.6 25.4 12.0 2.3 22.1 6.5 6.9 8.3
Scotland 2.2 547 10.2 30.5 17.0 3.8 17.4 7.3 5.3 8.4
Wales 3.2 363 14.9 26.5 16.5 3.0 16.5 7.2 6.6 8.8
UK 11.1 6,796 14.6 28.6 13.5 6.3 17.2 7.0 6.4 6.5
The percentage in each category has been calculated after excluding those patients with data not available
Table 1.9. Percentage distribution of primary renal diagnosis by age in the 2016 incident RRT cohort
Diagnosis
Percentage with diagnosis
Percentage
male
Age group
All18–,35 35–,45 45–,55 55–,65 65–,75 75–,85 85+
Diabetes 17.3 26.1 30.7 37.6 30.3 23.1 12.9 28.6 65
Glomerulonephritis 27.0 19.8 17.0 13.5 11.1 7.5 4.7 13.5 69
Pyelonephritis 8.5 6.7 4.2 4.4 7.0 7.6 9.4 6.4 60
Hypertension 3.9 5.4 6.9 5.1 6.3 8.2 8.6 6.3 69
Polycystic kidney 2.2 11.0 13.8 8.8 5.2 2.7 2.0 7.0 51
Renal vascular disease 0.6 1.1 1.5 3.5 8.1 13.0 21.1 6.5 67
Other 25.4 16.8 15.5 16.4 17.1 17.2 14.1 17.2 58
Uncertain aetiology 15.0 13.2 10.4 10.6 14.8 20.7 27.3 14.6 61
Percentages calculated after excluding those patients with data not available
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and a further 0.6% had stopped treatment, leaving 95.4%
of the original cohort still on RRT. Table 1.12a shows the
percentages on each treatment modality at 90 days both
as percentages of all of those starting RRT and then of
those still on treatment at 90 days. Expressed as percen-
tages of the whole incident cohort, 66.5% were on HD at
90 days, 19.6% were on PD and 9.3% had received a
transplant. Expressed as percentages of those still receiv-
ing RRT at 90 days, 69.8% were on HD, 20.5% on PD and
9.7% had received a transplant.
Figure 1.9 shows the modality breakdown with the HD
patients further subdivided. Of those still on RRT at 90
days, 41% were treated with hospital HD, 28% with satel-
lite HD, and only 0.4% were receiving home HD at this
early stage, equating to 32 patients (across 15 centres).
Table 1.12b shows the treatment breakdown at 90 days
by centre for a ﬁve year cohort (1 October 2011 to 30 Sep-
tember 2016). Using just 2016 incident patients, the
percentage of patients receiving RRT at 90 days with a
functioning transplant varied between centres from 0%
to 31% (between 2% and 31% for transplanting centres
and between 0% and 19% for non-transplanting centres).
The mean percentage of the incident cohort with a func-
tioning transplant at 90 days was greater in transplanting
compared to non-transplanting centres (12.1% vs 6.7%).
Table 1.10. Primary renal diagnosis RRT incidence rates (2016) per million population (unadjusted)
Diagnosis England N Ireland Scotland Wales UK
Diabetes 30.0 29.5 30.9 30.8 30.1
Glomerulonephritis 13.6 14.0 17.2 19.3 14.2
Pyelonephritis 6.7 8.1 5.4 7.7 6.7
Hypertension 7.3 2.7 3.9 3.5 6.7
Polycystic kidney 7.3 7.5 7.4 8.4 7.3
Renal vascular disease 6.4 9.7 8.5 10.3 6.8
Other 17.9 25.8 17.6 19.3 18.1
Uncertain aetiology 15.7 19.3 10.4 17.3 15.4
Data not available 15.0 4.8 2.2 3.9 13.1
All 120 121 103 120 119
The overall rates per country may be slightly different to those in table 1.2 as Cambridge (due to missing data) and Colchester (due to high
percentage with uncertain aetiology) have been excluded from both the numerator and the denominator here
Table 1.11. Treatment at start and at 90 days by year of start
Start
HD
(%)
PD
(%)
Transplant
(%)
Day 0 treatment
2011 72.7 20.4 6.9
2012 72.8 19.5 7.7
2013 71.9 19.3 8.8
2014 71.9 19.9 8.3
2015 73.0 19.3 7.7
2016 72.4 20.3 7.4
Day 90 treatment
Oct 2010 to end Sept 2011 70.9 20.5 8.6
Oct 2011 to end Sept 2012 70.9 20.1 9.0
Oct 2012 to end Sept 2013 70.0 19.9 10.2
Oct 2013 to end Sept 2014 69.7 20.1 10.2
Oct 2014 to end Sept 2015 71.3 19.4 9.3
Oct 2015 to end Sept 2016 69.8 20.5 9.7
Table 1.12a. RRT modality at 90 days by country (incident cohort 1/10/2015 to 30/09/2016)
Status at 90 days of all patients who started RRT (%)
Status at 90 days of only those
patients still on RRT (%)
Centre N HD PD Tx
Recovered/
discontinued Died HD PD Tx
England 6,414 65.8 20.1 9.3 0.6 4.1 69.1 21.1 9.8
N Ireland 245 65.3 15.9 14.7 2.0 2.0 68.1 16.6 15.3
Scotland 603 72.4 14.9 8.8 0.0 3.8 75.3 15.5 9.1
Wales 387 70.0 19.6 5.7 * * 73.4 20.6 6.0
UK 7,649 66.6 19.6 9.3 0.6 4.0 69.8 20.5 9.7
*Values suppressed due to small numbers (primary or secondary suppression)
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Table 1.12b. RRT modality at 90 days by centre (incident cohort 1/10/2011 to 30/09/2016)
Percentage
who had died
Percentage of patients still on RRT at 90 days, by modality
Centre N by 90 days HD PD Tx
England
B Heart 560 5 74 23 3
B QEH 1,147 2 73 18 9
Basldn 218 4 * 25 *
Bradfd 399 4 77 13 10
Brightn 703 6 70 23 7
Bristol 765 5 71 18 11
Camb 418 3 64 10 26
Carlis 179 * 54 40 6
Carsh 1,237 6 74 20 7
Chelms 244 * * 20 *
Colchr 157 7 * * *
Covnt 574 8 62 28 10
Derby 383 3 56 41 2
Donc 258 4 73 24 2
Dorset 374 1 68 27 4
Dudley 256 2 * 34 *
Exeter 657 3 74 20 6
Glouc 339 2 71 26 3
Hull 492 4 60 32 8
Ipswi 219 3 64 29 7
Kent 676 5 72 18 11
L Barts 1,459 4 64 29 7
L Guys 763 2 73 10 17
L Kings 764 2 71 25 4
L Rfree 1,142 4 61 27 11
L St.G 462 5 76 14 10
L West 1,736 2 82 7 10
Leeds 815 5 66 15 19
Leic 1,335 5 71 17 13
Liv Ain 306 10 69 28 3
Liv Roy 590 8 57 25 18
M RI 939 5 62 19 19
Middlbr 573 5 79 8 13
Newc 551 6 69 20 10
Norwch 437 5 79 18 4
Nottm 560 5 55 30 15
Oxford 913 4 59 23 17
Plymth 280 6 64 22 14
Ports 975 3 71 17 12
Prestn 760 4 72 16 12
Redng 486 5 60 32 8
Salford 754 4 63 25 11
Sheff 739 4 78 14 8
Shrew 296 6 69 28 3
Stevng 699 6 79 12 9
Sthend 181 6 69 26 5
Stoke 519 6 71 26 3
Sund 335 2 83 11 6
Truro 252 8 74 18 9
Wirral 296 14 74 21 5
Wolve 403 6 61 37 2
York 293 3 62 24 14
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Table 1.13 gives the HD/PD breakdown by age group
for patients receiving dialysis at 90 days (incident cohort
1/10/2013 to 30/09/2016). The percentage on PD at
90 days was about 50% higher in patients aged under
65 years than in older patients (27% vs 18%). In both
age groups there was a lot of variability between centres
in the percentage on PD. There were a small number of
centres where the percentage of patients treated with
PD was the same as, or higher in the over 65s than the
under 65s. Not all of these were centres with a high use
of PD.
Modality change over time
Table 1.14 gives the breakdown of status/treatment
modality at four subsequent time points by initial treat-
ment type for patients starting RRT in 2011. Fifty-three
percent of patients who started on HD had died within
ﬁve years of starting. This compared to 35% and 5% for
those starting on PD or transplant respectively. Of the
patients starting on PD, 91% were on PD at 90 days
but this percentage dropped sharply at the later time
Table 1.12b. Continued
Percentage
who had died
Percentage of patients still on RRT at 90 days, by modality
Centre N by 90 days HD PD Tx
N Ireland
Antrim 169 4 80 16 4
Belfast 427 2 58 13 29
Newry 117 5 * 32 *
Ulster 144 8 * 13 *
West NI 162 3 77 17 5
Scotland
Abrdn 277 4 * 20 *
Airdrie 292 * * 16 *
D & Gall 70 * 60 40 0
Dundee 218 2 * 17 *
Edinb 422 4 70 11 19
Glasgw 940 3 76 11 13
Inverns 108 * 71 24 5
Klmarnk 202 6 * 22 *
Krkcldy 180 3 * 16 *
Wales
Bangor 114 4 * 21 *
Cardff 844 5 72 17 11
Clwyd 114 6 74 22 5
Swanse 611 5 75 20 5
Wrexm 197 4 66 27 6
England 30,868 4 70 21 10
N Ireland 1,019 4 69 16 14
Scotland 2,709 3 76 15 8
Wales 1,880 5 73 20 8
UK 36,476 4 70 20 10
*Values suppressed due to small numbers (primary or secondary suppression)
Transplant
9.7%
PD
20.5%
Home HD
0.4%
Satellite HD
27.9%
Hosp HD
41.5%
Fig. 1.9. RRT modality at 90 days (incident cohort 1/10/2015 to
30/09/2016)
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points. In contrast, 90% of patients starting with a trans-
plant were also transplant patients at the ﬁve year time
point.
Renal function at the time of starting RRT
The mean eGFR at initiation of RRT in 2016 was
7.4 ml/min/1.73 m2. This was markedly lower than the
8.5 ml/min/1.73 m2 reported last year. This difference is
due to the use of the CKD-EPI rather than the MDRD
formula. By the MDRD method the mean eGFR was
8.5 ml/min/1.73 m2 in 2016. The mean eGFR at initiation
of RRT is shown by age group in ﬁgure 1.10.
Figure 1.11 shows serial data from centres reporting to
the UKRR every year since 2007. There has been a
tendency for patients to start PD at higher eGFRs than
HD recipients, seen again in 2016 (7.5 vs 7.1 ml/min/
1.73 m2).
Some caution should be applied to the analysis of
eGFR at the start of RRT as data were only available for
less than half of the incident patients (approximately
Table 1.13. Modality split of patients on dialysis at 90 days (incident cohort 1/10/2013 to 30/09/2016)
Age ,65 (%) Age 565 (%)
Centre HD PD HD PD
England
B Heart 65 35 80 20
B QEH 74 26 86 14
Basldn 69 31 76 24
Bradfd 84 16 93 8
Brightn 76 24 79 21
Bristol 74 26 84 17
Carlis 60 40 54 46
Carsh 72 28 85 16
Chelms 75 25 78 22
Colchr 100 0 100 0
Covnt 65 36 73 27
Derby 49 51 69 32
Donc 74 26 78 22
Dorset 71 29 75 25
Dudley 54 46 72 28
Exeter 68 32 82 18
Glouc 61 39 78 22
Hull 56 44 74 26
Ipswi 67 33 67 33
Kent 74 26 86 14
L Barts 67 33 74 26
L Guys 89 11 90 10
L Kings 70 30 78 22
L Rfree 61 39 70 30
L St.G 88 12 83 18
L West 90 10 91 9
Leeds 75 25 88 12
Leic 80 20 85 15
Liv Ain 58 42 79 21
Liv Roy 68 32 76 24
M RI 74 26 83 17
Middlbr 85 15 93 7
Newc 74 26 76 24
Norwch 75 26 88 12
Nottm 56 44 79 21
Oxford 62 38 79 21
Plymth 72 28 76 24
Ports 76 24 86 14
Prestn 80 20 83 17
Age ,65 (%) Age 565 (%)
Centre HD PD HD PD
Redng 56 44 72 28
Salford 67 33 74 26
Sheff 84 16 88 12
Shrew 52 48 81 19
Stevng 84 16 94 6
Sthend 69 31 67 33
Stoke 63 37 80 21
Sund 86 14 94 7
Truro 76 24 89 11
Wirral 71 29 87 13
Wolve 59 41 74 26
York 61 39 80 20
N Ireland
Antrim 72 28 91 9
Belfast 75 25 84 16
Newry 78 22 65 36
Ulster 80 20 87 13
West NI 85 15 85 15
Scotland
Abrdn 71 29 96 4
Airdrie 84 17 84 16
D & Gall 57 44 59 41
Dundee 81 19 83 17
Edinb 86 14 85 15
Glasgw 85 15 90 10
Inverns 72 28 84 16
Klmarnk 76 24 79 21
Krkcldy 73 27 88 12
Wales
Bangor 74 26 77 23
Cardff 74 26 87 13
Clwyd 63 38 86 14
Swanse 69 31 90 10
Wrexm 51 49 85 16
England 73 27 82 18
N Ireland 78 22 85 16
Scotland 80 20 86 14
Wales 69 31 87 13
UK 73 27 82 18
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3,100 for 2016) and almost half of these came from only
ten centres. Three-quarters of the values came from 20
centres. Further caution should be applied as some
patients may have an incorrect date of starting RRT
allocated and thus, the eGFR used for analysis may
have been taken whilst they were already receiving
RRT. This analysis is presented despite these deﬁciencies
for comparision with historical data. Completeness of
eGFR data and accuracy of start date are anticipated to
improve with the introduction of realtime data down-
loads and more complete collection of HD sessional data.
3. Late presentation and delayed referral of incident
patients
Introduction
Late presentation to a nephrologist is regarded as a
negative aspect in renal care. It can be deﬁned in a
number of ways as it has a range of possible causes.
There are many patients with CKD who are regularly
monitored in primary or secondary care and whose
referral to nephrology services is delayed (delayed or
Table 1.14. Initial and subsequent modalities for patients starting RRT in 2011*
Percentage
First treatment N Later modality 90 days 1 year 3 years 5 years
HD 4,864 HD 90 73 47 28
PD 2 4 1 1
Transplant 1 5 13 17
Recovered/discontinued 0 1 2 1
Died 6 18 37 53
PD 1,370 HD 6 15 20 17
PD 91 67 28 10
Transplant 1 10 30 37
Recovered/discontinued 0 0 1 1
Died 2 7 22 35
Transplant 448 HD 0 1 4 5
PD 1 0
Transplant 98 97 92 90
Died 1 1 4 5
*Cambridge excluded as ﬁve year follow up not available
Light grey shading indicates proportion of individuals maintained on their initial modality
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Fig. 1.10. Mean eGFR at start of RRT (2016) by age group
Note, for this report the CKD-EPI method was used for the ﬁrst time
rather than the MDRD method
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late referral). Other patients present late to medical
services with either such slowly progressive disease as
to have remained asymptomatic for many years or with
rapidly progressive kidney disease. The main analyses
presented here do not differentiate between these groups
and include any patient ﬁrst seen by renal services within
90 days of starting RRT for ERF as ‘late presentation’.
One analysis attempts to capture ‘late referrals’: it
shows the percentage presenting within 90 days of start-
ing RRT after excluding conditions that are likely to
present with rapid decline in renal function.
Methods
Date ﬁrst seen by a nephrologist has not been collected from
the Scottish Renal Registry and so Scottish centres were excluded
from these analyses. Data were included for incident patients in
English, Welsh or Northern Irish centres in the years 2015 to
2016. This two year cohort was used for most of the analyses in
order to make the late presentation percentages more reliably
estimated and to allow these to be shown for subgroups of patients.
The date ﬁrst seen in a renal centre and the date of starting RRT
were used to deﬁne the late presenting cohort. A small amount
of data was excluded because of actual or potential inconsistencies.
Only data from those centres with 75% or more completeness for
the relevant year were used. Data were excluded if more than 10%
of patients were reported to have started RRT on the same date as
the ﬁrst presentation. This was because investigation has shown
that this is likely due to misunderstanding on the part of the
renal centres resulting in incorrect recording of data. After these
exclusions, data on 10,966 patients were available for analysis.
Presentation times of 90 days or more before start were deﬁned
as early presentation and times of less than 90 days were deﬁned
as late presentation.
Estimated glomerular ﬁltration rate (eGFR) at the start of RRT
was studied amongst patients with eGFR data within 14 days
before the start of RRT. The eGFR was calculated using the
CKD-EPI equation and the abbreviated 4 variable MDRD study
equation to allow comparison with previously reported values.
For the purpose of the eGFR calculation, patients who had missing
ethnicity, but a valid serum creatinine measurement were classed
as White. Due to their skewed distribution the eGFR values were
log transformed.
A mixture of old and new (2012) EDTA codes for primary
diagnoses were received from centres. For those people without
an old code, new codes (where available) were mapped back to
old codes. These codes were grouped into the same eight categories
as in previous reports, the details are given in appendix H:
Ethnicity and ERA-EDTA Coding (www.renalreg.org).
People with the following conditions were allocated to an
‘acute’ group in some analyses: crescentic (extracapillary) glomer-
ulonephritis (type I, II, III), nephropathy (interstitial) due to cis-
platinum, renal vascular disease due to malignant hypertension,
renal vascular disease due to polyarteritis, Wegener’s granuloma-
tosis, cryoglobulinemic glomerulonephritis, myelomatosis/light
chain deposit disease, Goodpasture’s syndrome, systemic sclerosis
(scleroderma), haemolytic ureaemic syndrome, multi-system
disease – other, tubular necrosis (irreversible) or cortical necrosis,
Balkan nephropathy, kidney tumour(s), and traumatic or surgical
loss of kidney(s).
Results
Data completeness
Table 1.15 shows the percentage completeness of data
for 2015 and 2016.
Late presentation by centre
Figure 1.12 shows that late presentation varied
between centres from 5% to 34% in patients starting
RRT in 2015 to 2016. The overall rate of late presentation
was 15.9% and reduced to 11.2% once those people with
diseases likely to present acutely were excluded.
Table 1.16 shows the overall percentage presenting late
for the combined 2015/2016 incident cohort, the percen-
tages presenting late amongst those patients deﬁned as
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not having an ‘acute diagnosis’ and the percentages
amongst non-diabetics (as PRD).
Considerable differences exist between centres in late
presentation rates. One centre (Birmingham Heartlands)
attained a late presentation rate of just under 5%. Two
centres (Wirral, York) reported that over 40% of their
incident patients were referred late. These differences
have implications for their regions and referral
pathways.
Late presentation in 2016 and the trend over time
There has been a steady decline nationally in the pro-
portion of patients presenting late to renal services, with
some centres achieving ,10% late presentation rates. In
2016, 72.1% of incident patients presented to nephrology
services over a year before they started RRT. The remain-
ing patients presented within a year of start, with 7.8% of
patients presenting within the 6–12 month window
before RRT, 4.5% within 3–6 months and 15.6% within
three months of RRT start. Figure 1.13 shows this break-
down by year for those 37 centres supplying data over
75% complete for each of the last six years. The ﬁgure
shows an increase over time in the percentage of patients
presenting a year or more before starting RRT. As shown
in previous reports this increase was even more marked
in the years before those shown in the ﬁgure. In 2005,
Table 1.15. Percentage completeness of time of presentation data (2015 and 2016 incident RRT patients) by centre
N Percentage completeness
Centre 2015 2016 2015 2016
England
B Heart 123 135 100.0 100.0
B QEH 245 238 100.0 100.0
Basldn 48 40 97.9 95.0
Bradfd 91 86 100.0 * 100.0
Brightn 144 150 95.1 98.0
Bristol 146 155 81.5 73.6
Carlis 46 35 100.0 94.3
Carsh 260 246 46.9 41.5
Chelms 51 53 98.0 90.6
Colchr 28 30 67.9 46.7
Covnt 111 128 92.8 96.1
Derby 64 86 98.4 100.0
Donc 39 62 100.0 98.4
Dorset 75 70 94.7 97.1
Dudley 51 53 100.0 100.0
Exeter 137 143 100.0 97.2
Glouc 72 66 100.0 93.9
Hull 121 93 99.2 100.0
Ipswi 67 42 16.4 23.8
Kent 143 141 100.0 100.0
L Barts 311 297 1.9* 1.4
L Guys 179 169 94.4 94.7
L Kings 180 152 99.4 99.3
L Rfree 239 238 98.7 96.6
L St.G 114 94 69.3 16.0
L West 337 385 99.4 99.5
Leeds 147 166 100.0 100.0*
Leic 270 324 100.0 98.8
Liv Ain 61 53 95.1 98.1
Liv Roy 141 111 91.5 99.1
M RI 198 219 97.0 94.5
Middlbr 134 101 99.3 100.0
Newc 125 135 100.0 100.0
Norwch 112 97 100.0* 96.9*
N Percentage completeness
Centre 2015 2016 2015 2016
Nottm 120 120 100.0 100.0
Oxford 195 218 100.0 99.5
Plymth 53 63 98.1 100.0
Ports 200 191 70.5 41.4
Prestn 163 133 97.6 97.0
Redng 87 96 100.0 100.0
Salford 173 188 11.6* 5.9
Sheff 146 151 98.0 99.3
Shrew 62 58 100.0 100.0
Stevng 136 165 100.0 99.4
Sthend 35 47 91.4 95.7
Stoke 116 107 94.0 98.1
Sund 63 94 98.4 98.9
Truro 70 50 100.0 100.0
Wirral 64 69 98.4* 97.1
Wolve 85 64 98.8 95.3
York 61 72 100.0 100.0
N Ireland
Antrim 36 41 100.0 100.0
Belfast 94 95 93.6 87.4
Newry 28 25 100.0 100.0
Ulster 33 30 100.0 100.0
West NI 39 35 100.0* 97.1
Wales
Bangor 29 25 100.0 100.0
Cardff 160 161 99.4 99.4
Clwyd 28 16 96.4 81.3
Swanse 136 124 100.0 100.0
Wrexm 45 49 100.0 100.0
England 6,439 6,479 82.0 80.6
N Ireland 230 226 80.4 94.2
Wales 398 375 99.5 98.9
E, W & NI 7,067 7,080 83.0 82.0
*Completeness data shown but data not used as .10% of patients with data reported as starting RRT on same date as ﬁrst presentation
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Table 1.16. Percentage of patients presenting to a nephrologist less than 90 days before RRT initiation and percentage presenting
less than a year before initiation (2015/2016 incident patients) by centre
Centre
N
with data
Percentage presenting ,90 days before start
Percentage presenting ,1 year
before startb
Overall (95% CI) Non-acutea Non-diab PRD (95% CI)
England
B Heart 258 4.7 (2.7–8.0) 3.9 6.2 13.2 (9.6–17.9)
B QEH 483 20.7 (17.3–24.6) 15.7 23.3 34.6 (30.5–38.9)
Basldn 85 17.7 (10.9–27.2) 14.1 23.7 31.8 (22.8–42.4)
Bradfd 86 11.6 (6.4–20.3) 10.7 16.0 16.3 (9.9–25.6)
Brightn 284 18.3 (14.2–23.2) 11.9 21.5 35.2 (29.9–40.9)
Bristol 119 15.1 (9.7–22.7) 9.6 18.4 22.7 (16.0–31.1)
Carlis 79 15.2 (8.8–24.9) 9.8 16.7 24.1 (15.9–34.7)
Chelms 98 17.4 (11.1–26.2) 15.7 19.2 38.8 (29.7–48.7)
Covnt 226 19.9 (15.2–25.6) 14.4 22.9 33.6 (27.8–40.0)
Derby 149 15.4 (10.5–22.2) 9.0 21.9 25.5 (19.2–33.1)
Donc 100 18.0 (11.6–26.8) 10.5 23.1 30.0 (21.8–39.7)
Dorset 139 18.0 (12.5–25.3) 11.7 21.2 32.4 (25.1–40.6)
Dudley 104 11.5 (6.7–19.2) 8.2 13.9 24.0 (16.8–33.2)
Exeter 276 12.7 (9.3–17.2) 8.5 14.3 23.2 (18.6–28.5)
Glouc 134 9.0 (5.2–15.1) 6.5 12.0 16.4 (11.1–23.7)
Hull 213 15.5 (11.2–21.0) 13.4 17.5 35.7 (29.5–42.3)
Kent 284 10.9 (7.8–15.1) 7.4 12.2 16.9 (13.0–21.7)
L Guys 329 14.6 (11.2–18.8) 10.6 18.3 27.1 (22.5–32.1)
L Kings 330 16.4 (12.8–20.8) 12.9 21.2 29.1 (24.4–34.2)
L Rfree 466 14.4 (11.5–17.9) 11.4 16.2 26.0 (22.2–30.1)
L West 718 16.9 (14.3–19.8) 13.8 21.0 31.3 (28.1–34.8)
Leeds 147 14.3 (9.5–20.9) 9.1 15.9 27.9 (21.2–35.7)
Leic 590 19.3 (16.3–22.7) 10.5 22.4 32.0 (28.4–35.9)
Liv Ain 110 15.5 (9.8–23.5) 9.3 20.2 21.8 (15.1–30.5)
Liv Roy 239 20.9 (16.2–26.5) 28.5 (23.1–34.5)
M RI 399 18.3 (14.8–22.4) 10.1 23.9 34.3 (29.8–39.1)
Middlbr 234 16.7 (12.4–22.0) 13.0 20.5 29.5 (24.0–35.6)
Newc 260 13.5 (9.8–18.2) 9.9 15.9 26.5 (21.5–32.2)
Nottm 240 15.0 (11.0–20.1) 9.1 18.1 23.8 (18.8–29.5)
Oxford 412 12.6 (9.8–16.2) 7.4 15.8 23.8 (19.9–28.1)
Plymth 115 16.5 (10.8–24.5) 12.9 19.1 29.6 (22.0–38.5)
Prestn 288 16.7 (12.8–21.4) 11.3 20.9 28.1 (23.2–33.6)
Redng 183 14.2 (9.9–20.1) 9.8 19.1 26.8 (20.9–33.7)
Sheff 293 19.1 (15.0–24.0) 13.2 23.6 30.4 (25.4–35.9)
Shrew 120 25.0 (18.1–33.5) 21.9 28.9 34.2 (26.3–43.1)
Stevng 300 16.3 (12.6–21.0) 9.5 21.1 22.3 (18.0–27.4)
Sthend 77 11.7 (6.2–21.0) 8.6 12.7 27.3 (18.5–38.2)
Stoke 214 15.4 (11.2–20.9) 8.1 17.8 35.1 (29.0–41.7)
Sund 155 7.7 (4.5–13.1) 5.3 9.2 25.2 (19.0–32.6)
Truro 120 19.2 (13.1–27.2) 16.8 24.4 32.5 (24.7–41.4)
Wirral 67 34.3 (24.0–46.4) 32.8 42.5 58.2 (46.2–69.4)
Wolve 145 17.9 (12.5–25.0) 15.4 22.2 32.4 (25.3–40.4)
York 133 21.1 (15.0–28.8) 19.1 22.4 42.1 (34.0–50.6)
N Ireland
Antrim 77 16.9 (10.1–26.9) 11.8 22.6 22.1 (14.2–32.7)
Belfast 171 11.7 (7.7–17.4) 6.2 13.6 20.5 (15.1–27.2)
Newry 53 17.0 (9.1–29.5) 15.2 21.4 26.4 (16.3–39.8)
Ulster 63 12.7 (6.5–23.4) 9.1 15.6 22.2 (13.6–34.1)
West NI 34 11.8 (4.5–27.5) 9.4 16.0 14.7 (6.3–30.8)
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only 52.6% of incident patients presented over a year
before they started RRT.
Characteristics of patients presenting late versus those
presenting early
In the combined 2015/2016 incident cohort, the
median age was a little lower in those presenting late
than those presenting early (table 1.17). The percentage
who were male was higher in the group presenting late
than those presenting early. There were large differences
in the percentages starting on PD and in haemoglobin
and eGFR at start with all three of these being lower in
late presenters than in early presenters. More detailed
analyses of haemoglobin at start of RRT and late presen-
tation can be found in chapter 7: Haemoglobin, Ferritin
and Erythropoietin in UK Adult Dialysis Patients in
2016. The ﬁnding of lower average eGFR in those
presenting late is in contrast to some of the studies in
the literature but many of those studies pre-date the era
of routine use of eGFR [5, 6]. A Cochrane review [7]
showed that eGFR was lower in RRT patients referred
Table 1.16. Continued
Centre
N
with data
Percentage presenting ,90 days before start
Percentage presenting ,1 year
before startb
Overall (95% CI) Non-acutea Non-diab PRD (95% CI)
Wales
Bangor 54 5.6 (1.8–15.9) 5.8 7.0 11.1 (5.1–22.6)
Cardff 319 13.5 (10.2–17.7) 10.5 16.3 23.5 (19.2–28.5)
Clwyd 40 7.5 (2.4–20.8) c 0.0 10.0 (3.8–23.8)
Swanse 260 17.7 (13.5–22.8) 12.1 23.2 28.9 (23.7–34.7)
Wrexm 94 11.7 (6.6–19.9) 7.1 13.9 21.3 (14.2–30.7)
England 9,801 16.1 (15.4–16.9) 11.4 19.3 28.7 (27.8–29.6)
N Ireland 398 13.6 (10.5–17.3) 9.4 16.7 21.4 (17.6–25.7)
Wales 767 13.8 (11.6–16.5) 10.2 17.0 23.5 (20.6–26.6)
E, W & NI 10,966 15.9 (15.2–16.6) 11.2 19.0 28.0 (27.2–28.9)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Min 4.7 3.9 0.0 10.0
Quartile 1 12.7 9.0 15.9 22.7
Quartile 3 17.9 13.1 22.3 32.0
Max 34.3 32.8 42.5 58.2
Blank cells – data for PRD not used due to high % with missing data or high % with uncertain aetiology
aNon-acute group excludes those diagnoses deﬁned as acute (see methods)
bThe remaining patients starting RRT therefore presented over 1 year beforehand
cValue suppressed due to small numbers
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Fig. 1.13. Late presentation rate by year (2011–2016)
Restricted to centres reporting continuous data for 2011–2016
Table 1.17. Patient characteristics amongst patients presenting
late (,90 days) compared with those presenting early (590
days) (2015/2016 incident patients)
,90 days 590 days p-value
Median age 63.8 64.9 0.01
Percentage male 65.8 62.3 0.01
Percentage starting on PD 9.7 22.4 .0.0001
Percentage on PD at 90 days 12.0 22.2 .0.0001
Mean haemoglobin at RRT
start (g/L)a
91 100 .0.0001
Mean eGFR at RRT start
(ml/min/1.73 m2)ab
6.7 7.5 .0.0001
aData only available for about 50% of patients
bNote, for this report the CKD-EPI method was used for the ﬁrst
time rather than the MDRD method
CKD-EPI estimated mean GFR at start approximately 1 ml/min/
1.73 m2 lower than MDRD
UK Renal Replacement Therapy Incidence
in 2016
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late (mean difference of 0.42 ml/min/1.73 m2) compared
to those presenting early (deﬁnition: more than six
months before starting RRT) consistent with UKRR data.
In the 2015/2016 cohort, the percentage of non-White
patients presenting late (,90 days) was lower than in
Whites (13.8% vs 16.3%: p = 0.005). The high incidence
of diabetes in non-Whites (patients with diabetes tended
to present earlier) explains some of the difference in pres-
entation time between the groups. When patients with
diabetes were excluded, the percentages presenting late
(,90 days) became 18.3% in non-White patients vs
19.5% in Whites (p = 0.3). Above age 45, the median
duration of pre-RRT care did not vary greatly with age
group (ﬁgure 1.14).
Primary renal disease and late presentation
In the 2015/2016 cohort, there were large differences
in late presentation rates between PRDs (Chi-squared
test p , 0.0001) (table 1.18). Patients with conditions
likely to present with rapid decline in renal function or
without available data had high rates of late presentation,
as anticipated. Those with diabetes and adult polycystic
kidney disease or pyelonephritis had low rates, in keeping
with the natural histories of these conditions.
Comorbidity and late presentation
In the 2015/2016 cohort, the percentage of patients
with no recorded comorbidity was similar amongst
early and late presenters (50.2% vs 51.8%: p = 0.4).
However, cardiovascular disease was less common and
liver disease and malignancy more common in patients
who presented late, compared with those who presented
early (table 1.19). This is in keeping with ﬁndings from
other studies [5–6, 8].
International comparisons
Figure 1.15 shows the crude RRT incidence rates
(including children) for 2015 for various countries. The
non-UK data are from the USRDS [9]; 2015 was the latest
year available at the time of writing. The UK incidence
rate was comparable with other Northern European
countries, Australia and New Zealand, but remained
markedly lower than other countries, most notably
Greece, Japan and the USA. There are numerous reasons
for these differences which have been documented and
explored in other ecological studies and summarised by
this review [10].
Survival of incident patients
See chapter 5: Survival and Causes of Death of UK
Adult Patients on Renal Replacement Therapy in 2016.
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Fig. 1.14. Median duration of pre-RRT care by age group
(incident patients 2015/2016)
Table 1.18. Late presentation by primary renal diagnosis
(2015/2016 incident patients)
Diagnosis N
Late presentation
N %
Uncertain aetiology 1,514 273 18.0
Diabetes 2,811 194 6.9
Glomerulonephritis 1,390 184 13.2
Other identiﬁed category 921 163 17.7
Polycystic kidney or
pyelonephritis
1,353 100 7.4
Renal vascular disease 1,227 121 9.9
Acute group 968 524 54.1
Data not available 361 105 29.1
Unlike elsewhere in the report: (i) the RVD group includes hyper-
tension, and (ii) polycystic kidney and pyelonephritis are grouped
together
For deﬁnition of acute group see methods
Table 1.19. Percentage prevalence of speciﬁc comorbidities
amongst patients presenting late (,90 days) compared with
those presenting early (590 days) (2015/2016 incident patients)
Comorbidity ,90 days 590 days p-value
Ischaemic heart disease 13.0 20.6 ,0.0001
Cerebrovascular disease 5.9 10.4 ,0.0001
Peripheral vascular disease 8.3 11.5 0.003
Diabetes (not a cause of ERF) 10.6 10.7 0.9
Liver disease 5.6 3.4 0.001
Malignancy 19.3 12.4 ,0.0001
COPD 8.4 7.9 0.6
Smoking 10.7 13.0 0.05
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4. Acute haemodialysis
Methods
This section utilises sessional HD data alongside treatment
timeline codes. HD sessional data were submitted to the UKRR
by renal centres in England, as mandated by NHS England.
Centres in Northern Ireland and Wales provided data voluntarily.
Centres in Scotland did not provide HD sessional data. Centres
were asked to report details related to each HD session, including
vascular access used and blood pressure before and after the
session (data not shown).
The approach used to deﬁne HD as acute or for ERF was based
purely on timeline codes (ﬁgure 1.16). Sessional HD data were
used to check for individuals who received HD without a timeline
entry and to check start dates. Where timeline and sessional dates
were inconsistent, it was not possible to determine whether this
was due to a missing acute HD code or an inaccurate ﬁrst timeline
entry. As such, neither the dates nor content of timelines were
corrected using sessional HD data.
Results
Timeline data from 2016 show 6,891 people received
their ﬁrst-ever HD session across 61 centres in England,
Wales and Northern Ireland. Of these HD starts, 2,581
(37.5%) were coded as acute and 4,310 (62.5%) as being
for ERF (ﬁgure 1.16).
Forty-one of the 52 (78.8%) adult renal centres in
England submitted HD sessional data. Of these, four sub-
mitted only acute HD sessions and one submitted data
for only 16.8% of patients. Five centres in Northern Ire-
land and ﬁve in Wales also submitted data, of which
two centres did not submit acute HD sessions. A table
of completeness of the HD sessional data is available in
appendix F: Additional Data Tables for 2016 new and
existing patients.
Of the 2,581 individuals who started acute HD, ses-
sional data were available for 2,332 (90.4%). Fifty-three
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Fig. 1.15. International comparison of RRT
incidence rates in 2015
Non-UK data from USRDS [9]
Recovery, death
or withdrawal
Death or
withdrawal
Time
RRT initiation Day 90
Acute HD
HD for ERF
Acute start
HD 2,581
(37.5%)
Started for
ERF 4,310
(62.5%)
Acute HD code
Code indicating HD for ERF
Key:
Timeline data
show 6,891
ﬁrst-ever HD
sessions
Never received
ERF code 1,791
(26.0%)
Received HD
for ERF 5,100
(74.0%)
Patient A
Patient B
Patient C
Patient D
Patient E
Fig. 1.16. Timeline codes and renal
outcomes for all 6,891 people who received
their ﬁrst-ever HD session in England,
Northern Ireland and Wales in 2016
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Table 1.20. Centre-level acute and chronic haemodialysis initiation
Centre
% of incident
patients who started
HD acutely
% of HD recipients
with ERF who
started on acute HD
% of acute HD
recipients who
developed ERF
Percentage of each category for which
sessional HD data were available
AHD ACHD CHD Total
Antrim 27.3 5.9 16.7 90.0 100.0 100.0 97.7
B Heart 25.6 24.7 95.5 0.0 100.0 100.0 98.8
B QEH 48.1 44.6 86.7 100.0 98.7 100.0 99.5
Bangor 26.3 12.5 40.0 66.7 100.0 100.0 94.7
Basldn 49.0 16.7 20.8 84.2 100.0 100.0 93.9
Belfast 34.8 27.1 69.6 85.7 100.0 100.0 98.5
Bradfd 47.4 24.2 35.6 86.2 68.8 0.0 37.9
Brightn 46.7 29.2 47.1 94.6 100.0 100.0 98.7
Bristol 43.9 20.0 32.0 98.0 95.8 100.0 98.8
Carlis 67.5 35.0 25.9 75.0 100.0 100.0 87.5
Carsh 48.9 23.8 32.6 100.0 100.0 99.3 99.6
Chelms 43.1 25.6 45.5 100.0 100.0 100.0 100.0
Colchr 25.0 10.0 33.3 100.0 100.0 100.0 100.0
Covnt 37.9 10.3 18.9 90.7 100.0 97.7 95.7
Derby 57.0 21.6 20.8 92.9 100.0 100.0 96.8
Donc 22.4 13.6 54.5 60.0 100.0 100.0 95.9
Dorset 40.0 16.7 30.0 100.0 100.0 100.0 100.0
Dudley 70.8 31.6 19.0 98.0 100.0 96.2 97.8
Exeter 53.4 19.8 21.6 95.0 100.0 98.9 97.4
Glouc 48.7 9.3 10.8 100.0 100.0 100.0 100.0
Hull 56.5 11.3 9.8 98.2 100.0 0.0 55.6
Ipswi 30.3 14.8 40.0 100.0 100.0 100.0 100.0
Kent 33.9 29.6 82.1 100.0 100.0 98.7 99.1
L Barts 1.6 0.5 33.3 0.0 0.0 0.0 0.0
L Guys 3.7 0.8 20.0 100.0 100.0 99.2 99.3
L Kings 39.4 19.6 37.5 94.3 100.0 100.0 98.6
L Rfree 48.0 37.2 64.0 96.8 100.0 98.9 98.9
L St.G 25.8 5.5 16.7 0.0 0.0 0.0 0.0
L West 1.6 1.0 60.0 100.0 100.0 99.0 99.0
Leeds 62.1 30.3 26.5 97.0 94.4 0.0 59.8
Leic 38.4 11.4 20.6 97.1 100.0 99.0 98.5
Liv Ain 15.7 2.3 12.5 0.0 0.0 0.0 0.0
Liv Roy 25.8 8.3 26.1 0.0 0.0 0.0 0.0
M RI 27.9 8.4 23.6 0.0 15.4 21.8 16.8
Middlbr 44.1 12.0 17.3 95.3 100.0 100.0 98.3
Newc 52.6 7.8 7.6 91.8 100.0 100.0 96.0
Newry 36.0 15.8 33.3 83.3 100.0 100.0 96.0
Norwch 10.8 10.8 100.0 0.0 0.0 0.0 0.0
Nottm 66.4 32.4 24.2 96.0 100.0 98.0 97.3
Oxford 18.1 5.4 25.9 60.0 100.0 95.1 90.6
Plymth 47.1 12.2 15.6 100.0 80.0 100.0 98.5
Ports 35.9 15.9 33.8 100.0 100.0 100.0 100.0
Prestn 7.6 3.0 37.5 0.0 0.0 0.0 0.0
Redng 43.6 22.8 38.2 100.0 100.0 100.0 100.0
Salford 36.5 10.8 21.1 100.0 100.0 99.0 99.4
Sheff 3.0 0.0 0.0 0.0 0.0 0.0 0.0
Shrew 67.9 27.0 17.5 95.7 100.0 100.0 97.6
Stevng 52.8 23.9 28.1 100.0 100.0 98.0 99.1
Sthend 36.2 3.2 5.9 100.0 100.0 100.0 100.0
Stoke 16.7 10.3 57.1 0.0 0.0 0.0 0.0
Swanse 75.8 49.5 31.3 95.5 100.0 100.0 97.6
Truro 37.1 4.9 8.7 81.0 100.0 100.0 93.5
Ulster 55.0 14.3 13.6 73.7 100.0 100.0 87.5
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acute HD recipients (2.3%) had one or more HD sessions
preceding their timeline date of dialysis initiation. A
further 47 (2.0%) had sessional data available by at least
two weeks after the date of reaching ERF.
Of the 4,310 individuals who started HD for ERF, ses-
sional data were available for 3,010 (69.8%). One hundred
and forty-ﬁve individuals starting HD for ERF (4.8%) had
one or more HD sessions preceding the timeline date of
dialysis initiation. Only seven individuals were identiﬁed
who had sessional HD data, but no timeline entry for
acute or chronic HD. These seven individuals were
excluded from all analyses. It is not possible to further
quantify how many individuals received RRT in 2016
without a timeline code to indicate this.
Acute and chronic HD starts and progression to ERF
Of the 6,891 people who received their ﬁrst-ever HD
session in England, Northern Ireland and Wales in
2016, 5,100 (74.0%) received an ERF code. Of these,
4,310 (84.5%) started HD for ERF, whilst 790 (15.5%)
started HD acutely and were subsequently recoded as
having ERF. HD sessional data were available for 3,748
(73.5%). A further 1,791 individuals (26.0%) commenced
acute HD, but did not develop ERF. Sessional data were
available for 1,594 (89.0%) of these individuals. Data
relating to death and recovery will be presented in a
future report.
Excluding centres that contributed very incomplete or
no HD sessional data, 4,191 (79.7%) of 5,257 timeline and
sessional HD start dates were identical and 97.2% were
within two weeks of each other. Only 31 (0.6%) of the
timeline start dates were preceded by two or more
weeks of HD sessions.
Table 1.20 presents data for all HD starters at centre
level. There was large variation in acute HD use reported
by centres, with the percentage of HD starters who
received acute HD ranging between 1.6% and 75.8%.
The proportion of patients who developed ERF after
starting acute HD ranged between 0.0% and 49.5%.
Demography and clinical details of individuals who
received only acute HD
Table 1.21 presents demographic and clinical data for
the 1,791 individuals who commenced acute HD, but did
not progress to ERF. Overall, 62.5% were male and the
median age was 70.1 years. Forty-six percent had no
cause for AKI coded and a further 16.9% had the cause
of their AKI coded non-speciﬁcally as ‘acute kidney
injury’. Seventy-one percent were white and 6.1% were
of minority ethnic background. Centres are anonymised
in table 1.21 due to the small numbers of patients in
some sub-categories and the potential risk of identiﬁca-
tion.
Discussion
The UK RRT incidence rate for 2016 was 118 pmp,
reﬂecting RRT initiation for 7,759 new patients with
ERF. This rate was lower than in 2015 (120 pmp),
with signiﬁcantly lower incidence in Scotland compared
with England. Diabetic renal disease remained the single
most common cause of renal failure treated by RRT
(28.6%), despite late presentation with this condition
being the lowest of all PRDs. More men than women
Table 1.20. Continued
Centre
% of incident
patients who started
HD acutely
% of HD recipients
with ERF who
started on acute HD
% of acute HD
recipients who
developed ERF
Percentage of each category for which
sessional HD data were available
AHD ACHD CHD Total
West NI 18.2 12.9 66.7 50.0 100.0 100.0 97.0
Wirral 12.1 0.0 0.0 0.0 0.0 0.0 0.0
Wolve 61.2 16.7 12.7 94.5 100.0 100.0 97.1
Wrexm 29.8 5.7 14.3 83.3 100.0 100.0 95.7
York 54.1 23.5 26.1 100.0 100.0 0.0 54.1
Total 37.5 15.5 30.6 89.0 93.4 69.8 77.5
Ten centres supplied no HD sessional data and four supplied acute sessional data only. Three centres do not use acute timeline codes and
are not included in this table
HD – haemodialysis; ERF – established renal failure; AHD – started acute HD but never coded as ERF; ACHD – started acute HD and
recoded as ERF; CHD – started HD with ERF
UK Renal Replacement Therapy Incidence
in 2016
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Table 1.21. Demographic and clinical data for individuals who commenced acute haemodialysis, sorted by number of patients
Centre N % male
Cause of acute kidney injury (%) Ethnicity (%)
Median
ageAKI Hypvol
Circ.
fail Sepsis Rhabdo Toxicity Other Missing
Non-
White White Missing
1 10 60 10 0 10 10 0 10 60 0 0 100 0 64
2 12 42 8 0 0 8 0 0 17 67 17 83 0 70
3 12 75 8 0 0 0 0 0 0 92 8 67 25 68
4 12 67 0 17 0 33 0 0 17 33 0 67 33 74
5 16 63 38 0 0 6 0 6 19 31 13 88 0 71
6 17 59 0 0 0 0 0 0 0 100 6 94 0 57
7 19 47 5 0 5 16 0 11 21 42 5 68 26 71
8 19 58 16 0 21 16 0 11 37 0 0 100 0 76
9 20 55 5 0 5 10 0 0 15 65 0 100 0 68
10 20 80 0 0 0 0 0 0 5 95 20 60 20 62
11 20 65 0 0 0 10 10 5 0 75 10 80 10 68
12 21 76 38 5 0 0 0 0 57 0 0 91 10 74
13 21 52 5 0 0 10 5 5 29 48 14 67 19 72
14 21 67 81 0 0 0 0 0 5 14 0 100 0 65
15 27 63 7 4 4 15 0 0 33 37 0 100 0 70
16 29 59 0 0 0 0 0 0 3 97 3 0 97 65
17 31 58 7 0 0 0 3 0 45 45 23 61 16 72
18 33 58 21 3 0 21 0 0 39 15 6 91 3 73
19 34 59 0 0 0 0 0 0 0 100 0 0 100 69
20 35 71 0 3 3 3 0 0 23 69 14 54 31 67
21 37 76 35 0 0 8 11 11 27 8 3 81 16 70
22 42 69 12 2 2 2 2 0 36 43 10 74 17 68
23 42 45 60 0 2 7 7 0 10 14 19 76 5 61
24 43 51 0 0 0 0 0 0 21 79 9 84 7 73
25 43 70 0 0 0 0 0 0 5 95 0 100 0 64
26 43 58 0 0 0 0 0 0 12 88 2 77 21 75
27 45 71 56 0 0 22 9 4 9 0 7 93 0 68
28 47 79 62 0 2 2 4 0 6 23 4 94 2 76
29 51 65 0 0 0 2 0 0 28 71 6 78 16 74
30 51 57 31 2 0 14 4 0 24 26 4 88 8 74
31 55 62 2 0 0 0 0 0 0 98 0 4 96 72
32 55 66 16 6 9 20 2 2 42 4 6 89 6 68
33 75 64 63 0 0 4 0 1 29 3 13 83 4 69
34 80 58 15 13 3 19 4 11 21 15 0 71 29 72
35 82 61 16 6 1 12 5 5 26 29 10 74 16 71
36 85 65 17 8 8 20 7 9 28 2 2 94 4 67
37 91 57 0 0 0 0 0 0 2 98 9 71 20 73
38 100 58 0 0 0 0 0 1 2 97 0 3 97 69
39 104 67 3 0 0 3 1 0 21 72 10 79 12 72
40 110 64 30 2 4 15 6 2 42 1 1 76 23 72
Total 1,791 63 17 2 2 8 3 2 21 46 6 71 23 70
Centres where N , 10 are not shown and centres are anonymised due do the small numbers of patients in some sub-categories and the
potential risk of identiﬁcation
N – number of individuals starting acute haemodialysis at centre; Hypvol. – hypovolaemia; Circ. fail – circulatory failure; Rhabdo.- rhabdo-
myolysis; Toxicity – nephrotoxicity; AKI – acute kidney injury
The category ‘Other’ for cause of AKI, groups all of the following answers: pyelonephritis, diabetic kidney disease, renovascular disease,
glomerulonephritis, hypertension, uncertain or ‘other’
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started RRT in every age group (overall 62.9% male,
37.1% female). Incidence amongst the over-65s, which
more than tripled between 1990 and 2005, appears to
have plateaued at approximately 320 pmp for the past
decade. Incidence amongst those aged under 45 has
also been stable. Meanwhile, incidence amongst 45 to
64-year olds continued to rise, albeit marginally between
2015 and 2016.
Whilst overall incidence has stabilised, both incidence
rates and the total number of new starters was highest in
older people. With ongoing population growth and
ageing, the incident RRT population is likely to expand
and age over the coming decades. The median age of all
incident patients in 2016 was 64.3 years, but this was
highly dependent on ethnicity (66.2 years for White inci-
dent patients; 58.7 years for non-White patients). There
was marked variation between CCG/HBs in the rates of
older people (.75) starting RRT. This may signify true
practice variation, reﬂective of uncertainty within the
renal community about the beneﬁts of dialysis for the
oldest patients. However, these data are not adjusted
for factors such as rates of comorbid illness or ethnicity
that differ between CCG/HBs, or the life-expectancy of
the general population, which varies across the UK. A
proportion of individuals who developed ERF received
comprehensive conservative care in place of renal
replacement therapy. Inclusion of CKD data will allow
estimation of this population in the near future and will
enhance the interpretation of RRT incidence rates.
The percentage of RRT patients at 90 days who had a
functioning transplant varied between centres from 0% to
31% (between 2% and 31% for transplanting centres and
between 0% and 19% for non-transplanting centres).
These data might be seen to represent that transplan-
tation was more likely for an individual who was
primarily looked after at a transplant centre. An alterna-
tive explanation is that some patients transplanted pre-
emptively were attributed to the incident cohort of their
transplanting centre, rather than that from which they
were referred.
Although large numbers of patients continued to
present late to renal centres, this proportion has dropped
substantially in the last decade, from 23.9% in 2006 to
15.6% in 2016. This may be a consequence of CKD guide-
lines published by NICE [11], the Quality and Outcomes
Framework (QOF) initiative (www.dh.gov.uk) raising
awareness of CKD amongst non-nephrologists and the
introduction of estimated GFR reporting. Late presen-
tation continued to fall and some centres reported rates
of ,10%. The proportion of late presenting individuals
who have acute or undetected disease is unknown. Corre-
spondingly, the amount of truly avoidable late presen-
tation is unquantiﬁed. The Health Foundation has
funded an initiative that ﬂags people with declining
kidney function to their GP, to ensure they have con-
sidered referral to a nephrologist (ASSIST-CKD [12]).
This initiative is being managed through Kidney
Research UK and the UKRR is leading the evaluation
to establish effectiveness.
In 2016, 1,791 individuals in England, Northern Ire-
land and Wales commenced acute HD, but did not
develop ERF. These individuals made up 26% of those
Table 1.22. Instructions for reporting centres regarding use of timeline codes to indicate dialysis initiation
1) Coding must be consistent between centres
2) The timeline should be used to record the date of ﬁrst dialysis or haemoﬁltration:
Acute dialysis codes: Example dialysis codes indicating ERF (not an exhaustive list)*
81 Acute HD 1 HD
82 Acute haemoﬁltration 3 Haemodiaﬁltration
83 Acute PD 11 CAPD
12 APD
3) For those who start with an acute code, a separate code must subsequently indicate:
ARF recovered – code 84
ARF stopped dialysis (without recovery of function) – code 85
Development of ERF (codes as listed above plus transplantation)
This code must not be backdated
*For a full list of treatment modality codes see: https://www.renalreg.org/datasets/the-uk-renal-registry-dataset/
CAPD – continuous ambulatory peritoneal dialysis; APD – automated peritoneal dialysis; ARF – acute renal failure
UK Renal Replacement Therapy Incidence
in 2016
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who received HD for the ﬁrst time during this period.
This summary statistic masks striking variation in the
reported use of and outcomes from acute HD between
centres. Clinical explanations for variation include case
mix, case selection and thresholds for initiating dialysis,
and the proportion of individuals treated with acute PD
or haemoﬁltration in intensive care units. It seems likely,
however, that inconsistent use of timeline codes contrib-
utes substantially to inter-centre variation.
Whether an individual is receiving dialysis for AKI or
ERF leaves considerable room for clinical interpretation,
especially amongst those with advanced CKD. It may be
that even a uniform approach to timeline coding cannot
adequately distinguish between these groups. Signiﬁcant
input from all contributing renal centres is necessary to
ensure data of adequate quality are returned to permit
accurate and meaningful conclusions. Since 2009, the
UKRR has asked clinicians to use the timeline ﬁeld on
their renal IT system to record the date of ﬁrst dialysis
or haemoﬁltration and separately, the date on which
the patient was deemed to have reached ERF. This allows
the distinction between patients who have an acute start
and those whose start on RRT was planned. If the patient
recovers renal function, an entry should be made in the
timeline (table 1.22). Centres should not backdate ERF
codes to the date of dialysis initiation, as this negatively
inﬂuences the quality of survival analyses.
Reassuringly, sessional HD data suggested that start
dates are precise for 79.7% and within two weeks for
97.2% of incident HD recipients. These low levels of
discordance are unlikely to meaningfully inﬂuence over-
all survival analyses for all HD recipients, although the
effect on other analyses (such as eGFR at start) may be
greater. The UKRR hopes to improve such analyses
with the introduction of realtime data downloads for
individuals with advanced CKD and more complete
collection of HD sessional data.
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